US20050106210A1 - Medical device with drug - Google Patents

Medical device with drug Download PDF

Info

Publication number
US20050106210A1
US20050106210A1 US10/989,946 US98994604A US2005106210A1 US 20050106210 A1 US20050106210 A1 US 20050106210A1 US 98994604 A US98994604 A US 98994604A US 2005106210 A1 US2005106210 A1 US 2005106210A1
Authority
US
United States
Prior art keywords
biologically active
stent
coating
active material
medical device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/989,946
Inventor
Ni Ding
Michael Helmus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Boston Scientific Scimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27062077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050106210(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/663,518 external-priority patent/US6120536A/en
Application filed by Boston Scientific Scimed Inc filed Critical Boston Scientific Scimed Inc
Priority to US10/989,946 priority Critical patent/US20050106210A1/en
Publication of US20050106210A1 publication Critical patent/US20050106210A1/en
Assigned to BOSTON SCIENTIFIC SCIMED, INC. reassignment BOSTON SCIENTIFIC SCIMED, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCIMED LIFE SYSTEMS, INC.
Assigned to SCIMED LIFE SYSTEMS, INC. reassignment SCIMED LIFE SYSTEMS, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: BOSTON SCIENTIFIC SCIMED, INC.
Assigned to BOSTON SCIENTIFIC SCIMED, INC. reassignment BOSTON SCIENTIFIC SCIMED, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCHNEIDER (USA) INC.
Assigned to SCHNEIDER (USA) INC. reassignment SCHNEIDER (USA) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HELMUS, MICHAEL N., DING, NI
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/141Plasticizers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222Steroids, e.g. corticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23Carbohydrates
    • A61L2300/236Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • A61L2300/608Coatings having two or more layers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622Microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/02Methods for coating medical devices

Definitions

  • the present invention relates generally to therapeutic expandable stent prosthesis for implantation in body lumens, e.g., vascular implantation and, more particularly, to a process for providing biostable elastomeric coatings on such stents which incorporate biologically active species having controlled release characteristics directly in the coating structure.
  • stent devices In surgical or other related invasive medicinal procedures, the insertion and expansion of stent devices in blood vessels, urinary tracts or other difficult to access places for the purpose of preventing restenosis, providing vessel or lumen wall support or reinforcement and for other therapeutic or restorative functions has become a common form of long-term treatment.
  • prosthesis are applied to a location of interest utilizing a vascular catheter, or similar transluminal device, to carry the stent to the location of interest where it is thereafter released to expand or be expanded in situ.
  • vascular catheter or similar transluminal device
  • These devices are generally designed as permanent implants which may become incorporated in the vascular or other tissue which they contact at implantation.
  • One type of self-expanding stent has a flexible tubular body formed of several individual flexible thread elements each of which extends in a helix configuration with the centerline of the body serving as a common axis.
  • the elements are wound in a common direction, but are displaced axially relative to each other and meet, under crossing a like number of elements also so axially displaced, but having the opposite direction of winding.
  • This configuration provides a resilient braided tubular structure which assumes stable dimensions upon relaxation. Axial tension produces elongation and corresponding diameter contraction that allows the stent to be mounted on a catheter device and conveyed through the vascular system as a narrow elongated device. Once tension is relaxed in situ, the device at least substantially reverts to its original shape.
  • Prosthesis of the class including a braided flexible tubular body are illustrated and described in U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al.
  • Implanted stents have also been used to carry medicinal agents, such as thrombolytic agents.
  • U.S. Pat. No. 5,163,952 to Froix discloses a thermal memoried expanding plastic stent device which can be formulated to carry a medicinal agent by utilizing the material of the stent itself as an inert polymeric drug carrier.
  • Pinchuk in U.S. Pat. No. 5,092,877, discloses a stent of a polymeric material which may be employed with a coating associated with the delivery of drugs.
  • Other patents which are directed to devices of the class utilizing bio-degradable or bio-sorbable polymers include Tang et al, U.S. Pat. No. 4,916,193, and MacGregor, U.S. Pat. No.
  • Sahatjian in U.S. Pat. No. 5,304,121 discloses a coating applied to a stent consisting of a hydrogel polymer and a preselected drug; possible drugs include cell growth inhibitors and heparin.
  • a further method of making a coated intravascular stent carrying a therapeutic material in which a polymer coating is dissolved in a solvent and the therapeutic material dispersed in the solvent and the solvent thereafter evaporated is described in Berg et al, U.S. Pat. No. 5,464,650, issued Nov. 5, 1995 and corresponding to European patent application 0 623 354 A1 published 09 Nov. 1994.
  • the above cross-referenced grandparent application supplies an approach that provides long-term drug release, i.e., over a period of days or even months, incorporated in a controlled-release system.
  • the parent application and present invention provide a process for coating such stents including techniques that enable the initial burst effect of drug elation to be controlled and the drug release kinetic profile associated with long-term therapeutic effect to be modified.
  • Metal stents of like thickness and weave generally have better mechanical properties than polymeric stents.
  • Metallic vascular stents braided of even relatively fine metal filament can provide a large amount of strength to resist inwardly directed circumferential pressure in blood vessels.
  • a much thicker-walled structure or heavier, denser filament weave is required. This, in turn, reduces the cross-sectional area available for flow through the stent and/or reduces the relative amount of open space available in the structure.
  • the process of the present invention is not limited in that respect and may be used to coat a wide variety of devices.
  • the present invention also applies, for example, to the class of stents that are not self-expanding including those which can be expanded, for instance, with a balloon.
  • Polymeric stents, of all kinds can be coated using the process.
  • the use of the invention is not considered or intended to be limited with respect either to stent design or materials of construction.
  • the present invention may be utilized with other types of implant prostheses.
  • Another object of the invention is to provide a process for coating a stent prosthesis using a biostable hydrophobic elastomer in which biologically active species are incorporated within a cured coating.
  • Still another object of the present invention is to provide a multi-layer coating in which the percentage of active material can vary from layer to layer.
  • a further object of the present invention is to control or modify aspects of the timed or time variable drug delivery from a stent coating by controlling average particle size in the biologically active species.
  • the present invention provides processes for producing a relatively thin layer of biostable elastomeric material in which an amount of biologically active material is dispersed as a coating on the surfaces of a deployable stent prosthesis.
  • the preferred stent to be coated is a self-expanding, open-ended tubular stent prosthesis.
  • the tubular body is formed of an open braid of fine single or polyfilament metal wire which flexes without collapsing and readily axially deforms to an elongate shape for transluminal insertion via a vascular catheter.
  • the stent resiliently attempts to resume predetermined stable dimensions upon relaxation in situ.
  • the coating is preferably applied as a mixture, solution or suspension of polymeric material and finely divided biologically active species dispersed in an organic vehicle or a solution or partial solution of such species in a solvent or vehicle for the polymer and/or biologically active species.
  • finally divided means any type or size of included material from dissolved molecules through suspensions, colloids and particulate mixtures.
  • the active material is dispersed in a carrier material which may be the polymer, a solvent, or both.
  • the coating is preferably applied as a plurality of relatively thin layers sequentially applied in relatively rapid sequence and is preferably applied with the stent in a radially expanded state.
  • the coating may further be characterized as a composite initial tie coat or undercoat and a composite topcoat.
  • the coating thickness ratio of the topcoat to the undercoat may vary with the desired effect and/or the elution system. Typically these are of different formulations.
  • the coating may be applied by dipping or spraying using evaporative solvent materials of relatively high vapor pressure to produce the desired viscosity and quickly establish coating layer thicknesses.
  • the preferred process is predicated on reciprocally spray coating a rotating radially expanded stent employing an air brush device.
  • the coating process enables the material to adherently conform to and cover the entire surface of the filaments of the open structure of the stent but in a manner such that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.
  • the coating is exposed to room temperature ventilation for a predetermined time (possibly one hour or more) for solvent vehicle evaporation. Thereafter the polymeric precuser material is cured at room temperature or elevated temperatures or the solvent evaporated away from the dissolved polymer as the case may be. Curing is defined as the process of converting the elastomeric or polymeric material into the finished or useful state by the application of heat and/or chemical agents which include physical-chemical charges. Where, for example, polyurethane thermoplastic elastomers are used, solvent evaporation can occur at room temperature rendering the polymeric material useful for controlled drug release without further curing.
  • Non-limiting examples of curing according to this definition include the application of heat and/or chemical agents and the evaporation of solvent which may induce physical and/or chemical changes.
  • the ventilation time and temperature for cure are determined by the particular polymer involved and particular drugs used.
  • silicone or polysiloxane materials such as polydimethylsiloxane
  • These materials are applied as pre-polymer in the coating composition and must thereafter be cured.
  • the preferred species have a relatively low cure temperatures and are known as a room temperature vulcanizable (RTV) materials.
  • RTV room temperature vulcanizable
  • Some polydimethylsiloxane materials can be cured, for example, by exposure to air at about 90° C. for a period of time such as 16 hours.
  • a curing step may be implemented both after application of a certain number of lower undercoat layers and the topcoat layers or a single curing step used after coating is completed.
  • the coated stents may thereafter be subjected to a postcure sterilization process which includes an inert gas plasma treatment, and then exposure to gamma radiation, electron beam, ethylene oxide (ETO) or steam sterilization may also be employed.
  • a postcure sterilization process which includes an inert gas plasma treatment, and then exposure to gamma radiation, electron beam, ethylene oxide (ETO) or steam sterilization may also be employed.
  • unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to about 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment.
  • inert gas argon, helium or mixture of them
  • a highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to about 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes.
  • the stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • the coated and cured stents are subjected to gamma radiation sterilization nominally at 2.5-3.5 Mrad.
  • the stents enjoy full resiliency after radiation whether exposed in a constrained or non-constrained status. It has been found that constrained stents subjected to gamma sterilization without utilizing the argon plasma pretreatment lose resiliency and do not recover at a sufficient or appropriate rate.
  • the elastomeric material that forms a major constituent of the stent coating should possess certain properties. It is preferably a suitable hydrophobic biostable elastomeric material which does not degrade and which minimizes tissue rejection and tissue inflammation and one which will undergo encapsulation by tissue adjacent to the stent implantation site.
  • Polymers suitable for such coatings include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes (including polycarbonate urethanes), thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and polyamide elastomers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention.
  • Agents suitable for incorporation-in include antithrobotics, anticoagulants, antiplatelet agents, thrombolytics, antiproliferatives, antinflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, antibiotics growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration.
  • the positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).
  • the preferred materials for fabricating the braided stent include stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemoried alloy material), and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy® and Phynox®. Further details concerning the fabrication and details of other aspects of the stents themselves, may be gleaned from the above referenced U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al. To the extent additional information contained in the above-referenced patents is necessary for an understanding of the present invention, they are deemed incorporated by reference herein.
  • polymer coating materials can be coordinated with biologically active species of interest to produce desired effects when coated on stents to be implanted in accordance with the invention.
  • Loadings of therapeutic materials may vary.
  • the mechanism of incorporation of the biologically active species into the surface coating, and egress mechanism depend both on the nature of the surface coating polymer and the material to be incorporated.
  • the mechanism of release also depends on the mode of incorporation.
  • the material may elute via interparticle paths or be administered via transport or diffusion through the encapsulating material itself.
  • “elution” is defined as any-process of release that involves extraction or release by direct contact of the material with bodily fluids through the interparticle paths connected with the exterior of the coating.
  • Transport or “diffusion” are defined to include a mechanism of release in which a material released traverses through another material.
  • the desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material.
  • the crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a crosslink structure of greater density will increase release time and reduce burst effect.
  • release kinetics can be affected by varying the average dispersed particle size.
  • the observed initial release rate or burst effect may be substantially reduced by using smaller particles, particularly if the particle size is controlled to be less than about 15 microns and the effect is even more significant in the particle size range of ⁇ 10 microns, especially when the coating thickness is not more than about 50 ⁇ m and drug loading is about 25-45 weight percent.
  • an unmedicated silicone thin top layer provides an advantage over drug containing top coat. Its surface has a limited porosity and is generally smooth, which may be less thrombogeneous and may reduce the chance to develop calcification, which occurs most often on the porous surface.
  • FIG. 1 is a schematic flow diagram illustrating the steps of the process of the invention
  • FIG. 2 represents a release profile for a multi-layer system showing the percentage of heparin released over a two-week period
  • FIG. 3 represents a release profile for a multi-layer system showing the relative release rate of heparin over a two-week period
  • FIG. 4 illustrates a profile of release kinetics for different drug loadings at similar coating thicknesses illustrating the release of heparin over a two-week period
  • FIG. 5 illustrates drug elution kinetics at a given loading of heparin over a two-week period at different coating thicknesses
  • FIG. 6 illustrates the release kinetics in a coating having a given tie-layer thickness for different top coat thicknesses in which the percentage heparin in the tie coat and top coats are kept constant;
  • FIG. 7 illustrates the release kinetics of several coatings having an average coating thickness of 25 microns and a heparin loading of 37.5% but using four different average particle sizes;
  • FIGS. 8-11 are photomicrographs of coated stent fragments for the coatings of FIG. 7 having a corresponding average particle size of 4 microns, 17 microns, 22 microns and 30 microns, respectively.
  • the stent coatings incorporating biologically active materials for timed delivery in situ in a body lumen of interest are preferably sprayed in many thin layers from prepared coating solutions or suspensions.
  • the steps of the process are illustrated generally in FIG. 1 .
  • the coating solutions or suspensions are prepared at 10 as will be described later.
  • the desired amount of crosslinking agent is added to the suspension/solution as at 12 and material is then agitated or stirred to produce a homogenous coating composition at 14 which is thereafter transferred to an application container or device which may be a container for spray painting at 16.
  • Typical exemplary preparations of coating solutions that were used for heparin and dexamethasone appear next.
  • Silicone was obtained as a polymer precursor in solvent (xylene) mixture.
  • the manufacturer crosslinker solution was added by using Pasteur P-pipet. The amount of crosslinker added was formed to effect the release rate profile. Typically, five drops of crosslinker solution were added for each five grams of silicone-xylene mixture.
  • the crosslinker may be any suitable and compatible agent including platinum and peroxide based materials. The solution was stirred by using the stirring rod until the suspension was homogenous and milk-like. The coating solution was then transferred into a paint jar in condition for application by air brush.
  • Silicone (35% solution as above) was weighed into a beaker on a Metler balance. The weight of dexamethasone free alcohol or acetate form was calculated by silicone weight multiplied by 0.35 and the desired percentage of dexamethasone (1 to 40%) and the required amount was then weighed.
  • W silicone solid /V THF 0.06 for a 10% dexamethasone coating solution.
  • the dexamethasone was weighed in a beaker on an analytical balance and half the total amount of THF was added. The solution was stirred well to ensure full dissolution of the dexamethasone. The stirred DEX-THF solution was then transferred to the silicone container. The beaker was washed with the remaining THF and this was transferred to the silicone container. The crosslinker was added by using a Pasteur pipet. Typically, five drops of crosslinker were used for five grams of silicone.
  • the application of the coating material to the stent was quite similar for all of the materials and the same for the heparin and dexamethasone suspensions prepared as in the above Examples.
  • the suspension to be applied was transferred to an application device, typically a paint jar attached to an air brush, such as a Badger Model 150, supplied with a source of pressurized air through a regulator (Norgren, 0-160 psi). Once the brush hose was attached to the source of compressed air downstream of the regulator, the air was applied. The pressure was adjusted to approximately 15-25 psi and the nozzle condition checked by depressing the trigger.
  • any appropriate method can be used to secure the stent for spraying and rotating fixtures were utilized successfully in the laboratory. Both ends of the relaxed stent were fastened to the fixture by two resilient retainers, commonly alligator clips, with the distance between the clips adjusted so that the stent remained in a relaxed, unstretched condition. The rotor was then energized and the spin speed adjusted to the desired coating speed, nominally about 40 rpm.
  • the spray nozzle was adjusted so that the distance from the nozzle to the stent was about 2-4 inches and the composition was sprayed substantially horizontally with the brush being directed along the stent from the distal end of the stent to the proximal end and then from the proximal end to the distal end in a sweeping motion at a speed such that one spray cycle occurred in about three stent rotations.
  • a pause of less than one minute normally about one-half minute, elapsed between layers.
  • the number of coating layers did and will vary with the particular application. For example, for a coating level of 3-4 mg of heparin per cm 2 of projected area, 20 cycles of coating application are required and about 30 ml of solution will be consumed for a 3.5 mm diameter by 14.5 cm long stent.
  • the rotation speed of the motor can be adjusted as can the viscosity of the composition and the flow rate of the spray nozzle as desired to modify the layered structure.
  • the best results have been obtained at rotational speeds in the range of 30-50 rpm and with a spray nozzle flow rate in the range of 4-10 ml of coating composition per minute, depending on the stent size. It is contemplated that a more sophisticated, computer-controlled coating apparatus will successfully automate the process demonstrated as feasible in the laboratory.
  • the tie layer makes up what is called the tie layer as at 18 and thereafter additional upper layers, which may be of a different composition with respect to bioactive material, the matrix polymeric materials and crosslinking agent, for example, are applied as the top layer as at 20.
  • the application of the top layer follows the same coating procedure as the tie layer with the number and thickness of layers being optional.
  • the thickness of any layer can be adjusted by modifying the speed of rotation of the stent and the spraying conditions.
  • the total coating thickness is controlled by the number of spraying cycles or thin coats which make up the total coat.
  • the coated stent is thereafter subjected to a curing step in which the pre-polymer and crosslinking agents cooperate to produce a cured polymer matrix containing the biologically active species.
  • the curing process involves evaporation of the solvent xylene, THF, etc. and the curing and crosslinking of the polymer.
  • Certain silicone materials can be cured at relatively low temperatures, (i.e. RT-50° C.) in what is known as a room temperature vulcanization (RTV) process. More typically, however, the curing process involves higher temperature curing materials and the coated stents are put into an oven at approximately 90° C. or higher for approximately 16 hours. The temperature may be raised to as high as 150° C. for dexamethasone containing coated stents.
  • the time and temperature may vary with particular silicones, crosslinkers, and biologically active species.
  • Stents coated and cured in the manner described need to be sterilized prior to packaging for future implantation.
  • gamma radiation is a preferred method particularly for heparin containing coatings; however, it has been found that stents coated and cured according to the process of the invention subjected to gamma sterilization may be too slow to recover their original posture when delivered to a vascular or other lumen site using a catheter unless a pretreatment step as at 24 is first applied to the coated, cured stent.
  • the pretreatment step involves an argon plasma treatment of the coated, cured stents in the unconstrained configuration.
  • the stents are placed in a chamber of a plasma surface treatment system such as a Plasma Science 350 (Himont/Plasma Science, Foster City, Calif.).
  • the system is equipped with a reactor chamber and RF solid-state generator operating at 13.56 mHz and from 0-500 watts power output and being equipped with a microprocessor controlled system and a complete vacuum pump package.
  • the reaction chamber contains an unimpeded work volume of 16.75 inches (42.55 cm) by 13.5 inches (34.3 cm) by 17.5 inches (44.45 cm) in depth.
  • unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment.
  • inert gas argon, helium or mixture of them
  • a highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes.
  • the stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • the stents are exposed to gamma sterilization at 2.5-3.5 Mrad.
  • the radiation may be carried out with the stent in either the radially non-constrained status—or in the radially constrained status.
  • the percentage in the tie layer is nominally from about 20-50% and that of the top layer from about 0-30% active material.
  • the coating thickness ratio of the top layer to the tie layer varies from about 1:10 to 1:2 and is preferably in the range of from about 1:6 to 1:3.
  • Suppressing the burst effect also enables a reduction in the drug loading or in other words, allows a reduction in the coating thickness, since the physician will give a bolus injection of antiplatelet/anticoagulation drugs to the patient during the stenting process.
  • the drug imbedded in the stent can be fully used without waste. Tailoring the first day release, but maximizing second day and third day release at the thinnest possible coating configuration will reduce the acute or subcute thrombosis.
  • FIG. 4 depicts the general effect of drug loading for coatings of similar thickness.
  • the initial elution rate increases with the drug loading as shown in FIG. 5 .
  • the release rate also increases with the thickness of the coating at the same loading but tends to be inversely proportional to the thickness of the top layer as shown by the same drug loading and similar tie-coat thickness in FIG. 6 .
  • FIGS. 7-11 The effect of average particle size is depicted in the FIGS. 7-11 in which coating layers with an average coating thickness of about 25 microns ( ⁇ m), prepared and sterilized as above, were provided with dispersed heparin particles (to 37.5% heparin) of several different average particle sizes.
  • FIG. 7 shows plots of elution kinetics for four different sizes of embedded heparin particles. The release took place in phosphate buffer (pH 7.4) at 37° C. The release rate using smaller, particularly 4-6 ⁇ m average sized particles noticeably reduces the initial rate or burst effect and thereafter the elution rate decreases more slowly with time. Average particle sizes above about 15 ⁇ m result in initial release rates approaching bolus elution. This, of course, is less desirable, both from the standpoint of being an unnecessary initial excess and for prematurely depleting the coating of deserved drug material.
  • the morphology of the coating surface also changes coatings containing larger particles ( FIGS. 9-11 ) have very rough and irregular surface characteristics. These surface irregularities may be more thrombogenic or exhibit an increased tendency to cause embolization when the corresponding stent is implanted in a blood vessel.
  • the average particle size should generally be controlled below about 15 ⁇ m to reduce the burst effect and preferably should be ⁇ about 10 ⁇ m for best results.
  • the 4-6 ⁇ m size worked quite successfully in the laboratory.
  • larger particle size can also be advantageously used, for instance, when the drug load is low, such as below 25 weight percent.
  • Elution kinetics can be adjusted by a combination of changing the particle size and changing the load or concentration of the dispersed drug material.
  • stent coatings can be prepared using a combination of two or more drugs and the drug release sequence and rate controlled.
  • antiproliferation drugs may be combined in the undercoat and anti-thrombotic drugs in the topcoat layer.
  • antiproliferation drugs for example, heparin
  • antiproliferation drugs will elute first followed by antiproliferation drugs, e.g. dexamethasone, to better enable safe encapsulation of the implanted stent.
  • heparin concentration measurement were made utilizing a standard curve prepared by complexing azure A dye with dilute solutions of heparin. Sixteen standards were used to compile the standard curve in a well-known manner.
  • the stents were immersed in a phosphate buffer solution at pH 7.4 in an incubator at approximately 37° C. Periodic samplings of the solution were processed to determine the amount of heparin eluted. After each sampling, each stent was placed in heparin-free buffer solution.
  • the allowable loading of the elastomeric material with heparin may vary, in the case of silicone materials heparin may exceed 60% of the total weight of the layer. However, the loading generally most advantageously used is in the range from about 10% to 45% of the total weight of the layer. In the case of dexamethasone, the loading may be as high as 50% or more of the total weight of the layer but is preferably in the range of about 0.4% to 45%.
  • the mechanism of incorporation of the biologically active species into a thin surface coating structure applicable to a metal stent is an important aspect of the present invention.
  • the need for relatively thick-walled polymer elution stents or any membrane overlayers associated with many prior drug elution devices is obviated, as is the need for utilizing biodegradable or reabsorbable vehicles for carrying the biologically active species.
  • the technique clearly enables long-term delivery and minimizes interference with the independent mechanical or therapeutic benefits of the stent itself.
  • Coating materials are designed with a particular coating technique, coating/drug combination and drug infusion mechanism in mind. Consideration of the particular form and mechanism of release of the biologically active species in the coating allow the technique to produce superior results. In this manner, delivery of the biologically active species from the coating structure can be tailored to accommodate a variety of applications.
  • any number of layers and combinations of loadings can be employed to achieve a desired release profile.
  • gradual grading and change in the loading of the layers can be utilized in which, for example, higher loadings are used in the inner layers.
  • layers can be used which have no drug loadings at all.
  • a pulsatile heparin release system may be achieved by a coating in which alternate layers containing heparin are sandwiched between unloaded layers of silicone or other materials for a portion of the coating.
  • each applied layer is typically from approximately 0.5 microns to 15 microns in thickness.
  • the total number of sprayed layers can vary widely, from less than 10 to more than 50 layers; commonly, 20 to 40 layers are included.
  • the total thickness of the coating can also vary widely, but can generally be from about 10 to 200 microns.
  • the polymer of the coating may be any compatible biostable elastomeric material capable of being adhered to the stent material as a thin layer
  • hydrophobic materials are preferred because it has been found that the release of the biologically active species can generally be more predictably controlled with such materials.
  • Preferred materials include silicone rubber elastomers and biostable polyurethanes specifically.

Abstract

A method of coating implantable open lattice metallic stent prosthesis is disclosed which includes sequentially applying a plurality of relatively thin outer layers of a coating composition comprising a solvent mixture of uncured polymeric silicone material and crosslinker and finely divided biologically active species, possibly of controlled average particle size, to form a coating on each stent surface. The coatings are cured in situ and the coated, cured prosthesis are sterilized in a step that includes preferred pretreatment with argon gas plasma and exposure to gamma radiation electron beam, ethylene oxide, steam.

Description

    I. CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a Continuation-In-Part of copending application Ser. No. 08/526,273, filed Sep. 11, 1995, and a Continuation-In-Part of copending application Ser. No. 08/424,884, filed Apr. 19, 1995, all portions of the parent applications not contained in this application being deemed incorporated by reference for any purpose. Cross-reference is also made to application Ser. No. 08/______, entitled “DRUG RELEASE STENT COATING AND PROCESS”, filed of even date and of common inventorship and assignee, that is also a Continuation-In-Part of both above-referenced patent applications. Any portion of that application that is not contained herein is also deemed to be incorporated by reference for any purpose.
  • BACKGROUND OF THE INVENTION
  • II. Field of the Invention
  • The present invention relates generally to therapeutic expandable stent prosthesis for implantation in body lumens, e.g., vascular implantation and, more particularly, to a process for providing biostable elastomeric coatings on such stents which incorporate biologically active species having controlled release characteristics directly in the coating structure.
  • II. Related Art
  • In surgical or other related invasive medicinal procedures, the insertion and expansion of stent devices in blood vessels, urinary tracts or other difficult to access places for the purpose of preventing restenosis, providing vessel or lumen wall support or reinforcement and for other therapeutic or restorative functions has become a common form of long-term treatment. Typically, such prosthesis are applied to a location of interest utilizing a vascular catheter, or similar transluminal device, to carry the stent to the location of interest where it is thereafter released to expand or be expanded in situ. These devices are generally designed as permanent implants which may become incorporated in the vascular or other tissue which they contact at implantation.
  • One type of self-expanding stent has a flexible tubular body formed of several individual flexible thread elements each of which extends in a helix configuration with the centerline of the body serving as a common axis. The elements are wound in a common direction, but are displaced axially relative to each other and meet, under crossing a like number of elements also so axially displaced, but having the opposite direction of winding. This configuration provides a resilient braided tubular structure which assumes stable dimensions upon relaxation. Axial tension produces elongation and corresponding diameter contraction that allows the stent to be mounted on a catheter device and conveyed through the vascular system as a narrow elongated device. Once tension is relaxed in situ, the device at least substantially reverts to its original shape. Prosthesis of the class including a braided flexible tubular body are illustrated and described in U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al.
  • Implanted stents have also been used to carry medicinal agents, such as thrombolytic agents. U.S. Pat. No. 5,163,952 to Froix discloses a thermal memoried expanding plastic stent device which can be formulated to carry a medicinal agent by utilizing the material of the stent itself as an inert polymeric drug carrier. Pinchuk, in U.S. Pat. No. 5,092,877, discloses a stent of a polymeric material which may be employed with a coating associated with the delivery of drugs. Other patents which are directed to devices of the class utilizing bio-degradable or bio-sorbable polymers include Tang et al, U.S. Pat. No. 4,916,193, and MacGregor, U.S. Pat. No. 4,994,071. Sahatjian in U.S. Pat. No. 5,304,121, discloses a coating applied to a stent consisting of a hydrogel polymer and a preselected drug; possible drugs include cell growth inhibitors and heparin. A further method of making a coated intravascular stent carrying a therapeutic material in which a polymer coating is dissolved in a solvent and the therapeutic material dispersed in the solvent and the solvent thereafter evaporated is described in Berg et al, U.S. Pat. No. 5,464,650, issued Nov. 5, 1995 and corresponding to European patent application 0 623 354 A1 published 09 Nov. 1994.
  • An article by Michael N. Helmus (a co-inventor of the present invention) entitled “Medical Device Design—A Systems Approach: Central Venous Catheters”, 22nd International Society for the Advancement of Material and Process Engineering Technical Conference (1990) relates to polymer/drug/membrane systems for releasing heparin. Those polymer/ drug/membrane systems require two distinct layers to function.
  • The above cross-referenced grandparent application supplies an approach that provides long-term drug release, i.e., over a period of days or even months, incorporated in a controlled-release system. The parent application and present invention provide a process for coating such stents including techniques that enable the initial burst effect of drug elation to be controlled and the drug release kinetic profile associated with long-term therapeutic effect to be modified.
  • Metal stents of like thickness and weave generally have better mechanical properties than polymeric stents. Metallic vascular stents braided of even relatively fine metal filament can provide a large amount of strength to resist inwardly directed circumferential pressure in blood vessels. In order for a polymer material to provide comparable strength characteristics, a much thicker-walled structure or heavier, denser filament weave is required. This, in turn, reduces the cross-sectional area available for flow through the stent and/or reduces the relative amount of open space available in the structure. In addition, when applicable, it is usually more difficult to load and deliver polymeric stents using vascular catheter delivery systems.
  • It will be noted, however, that while certain types of stents such as braided metal stents may be superior to others for some applications, the process of the present invention is not limited in that respect and may be used to coat a wide variety of devices. The present invention also applies, for example, to the class of stents that are not self-expanding including those which can be expanded, for instance, with a balloon. Polymeric stents, of all kinds can be coated using the process. Thus, regardless of particular detailed embodiments the use of the invention is not considered or intended to be limited with respect either to stent design or materials of construction. Further, the present invention may be utilized with other types of implant prostheses.
  • Accordingly, it is a primary object of the present invention to provide a coating process for coating a stent to be used as a deployed stent prosthesis, the coating being capable of long-term delivery of biologically active materials.
  • Another object of the invention is to provide a process for coating a stent prosthesis using a biostable hydrophobic elastomer in which biologically active species are incorporated within a cured coating.
  • Still another object of the present invention is to provide a multi-layer coating in which the percentage of active material can vary from layer to layer.
  • A further object of the present invention is to control or modify aspects of the timed or time variable drug delivery from a stent coating by controlling average particle size in the biologically active species.
  • Other objects and advantages of the present invention will become apparent to those skilled in the art upon familiarization with the specification and appended claims.
  • SUMMARY OF THE INVENTION
  • The present invention provides processes for producing a relatively thin layer of biostable elastomeric material in which an amount of biologically active material is dispersed as a coating on the surfaces of a deployable stent prosthesis. The preferred stent to be coated is a self-expanding, open-ended tubular stent prosthesis. Although other materials, including polymer materials, can be used, in the preferred embodiment, the tubular body is formed of an open braid of fine single or polyfilament metal wire which flexes without collapsing and readily axially deforms to an elongate shape for transluminal insertion via a vascular catheter. The stent resiliently attempts to resume predetermined stable dimensions upon relaxation in situ.
  • The coating is preferably applied as a mixture, solution or suspension of polymeric material and finely divided biologically active species dispersed in an organic vehicle or a solution or partial solution of such species in a solvent or vehicle for the polymer and/or biologically active species. For the purpose of this application, the term “finally divided” means any type or size of included material from dissolved molecules through suspensions, colloids and particulate mixtures. The active material is dispersed in a carrier material which may be the polymer, a solvent, or both. The coating is preferably applied as a plurality of relatively thin layers sequentially applied in relatively rapid sequence and is preferably applied with the stent in a radially expanded state. In some applications the coating may further be characterized as a composite initial tie coat or undercoat and a composite topcoat. The coating thickness ratio of the topcoat to the undercoat may vary with the desired effect and/or the elution system. Typically these are of different formulations.
  • The coating may be applied by dipping or spraying using evaporative solvent materials of relatively high vapor pressure to produce the desired viscosity and quickly establish coating layer thicknesses. The preferred process is predicated on reciprocally spray coating a rotating radially expanded stent employing an air brush device. The coating process enables the material to adherently conform to and cover the entire surface of the filaments of the open structure of the stent but in a manner such that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.
  • The coating is exposed to room temperature ventilation for a predetermined time (possibly one hour or more) for solvent vehicle evaporation. Thereafter the polymeric precuser material is cured at room temperature or elevated temperatures or the solvent evaporated away from the dissolved polymer as the case may be. Curing is defined as the process of converting the elastomeric or polymeric material into the finished or useful state by the application of heat and/or chemical agents which include physical-chemical charges. Where, for example, polyurethane thermoplastic elastomers are used, solvent evaporation can occur at room temperature rendering the polymeric material useful for controlled drug release without further curing. Non-limiting examples of curing according to this definition include the application of heat and/or chemical agents and the evaporation of solvent which may induce physical and/or chemical changes.
  • The ventilation time and temperature for cure are determined by the particular polymer involved and particular drugs used. For example, silicone or polysiloxane materials (such as polydimethylsiloxane) have been used successfully. These materials are applied as pre-polymer in the coating composition and must thereafter be cured. The preferred species have a relatively low cure temperatures and are known as a room temperature vulcanizable (RTV) materials. Some polydimethylsiloxane materials can be cured, for example, by exposure to air at about 90° C. for a period of time such as 16 hours. A curing step may be implemented both after application of a certain number of lower undercoat layers and the topcoat layers or a single curing step used after coating is completed.
  • The coated stents may thereafter be subjected to a postcure sterilization process which includes an inert gas plasma treatment, and then exposure to gamma radiation, electron beam, ethylene oxide (ETO) or steam sterilization may also be employed.
  • In the plasma treatment, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to about 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to about 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • After the argon plasma pretreatment, the coated and cured stents are subjected to gamma radiation sterilization nominally at 2.5-3.5 Mrad. The stents enjoy full resiliency after radiation whether exposed in a constrained or non-constrained status. It has been found that constrained stents subjected to gamma sterilization without utilizing the argon plasma pretreatment lose resiliency and do not recover at a sufficient or appropriate rate.
  • The elastomeric material that forms a major constituent of the stent coating should possess certain properties. It is preferably a suitable hydrophobic biostable elastomeric material which does not degrade and which minimizes tissue rejection and tissue inflammation and one which will undergo encapsulation by tissue adjacent to the stent implantation site. Polymers suitable for such coatings include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes (including polycarbonate urethanes), thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and polyamide elastomers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention.
  • Agents suitable for incorporation-include antithrobotics, anticoagulants, antiplatelet agents, thrombolytics, antiproliferatives, antinflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, antibiotics growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration. The positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).
  • The preferred materials for fabricating the braided stent include stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemoried alloy material), and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy® and Phynox®. Further details concerning the fabrication and details of other aspects of the stents themselves, may be gleaned from the above referenced U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al. To the extent additional information contained in the above-referenced patents is necessary for an understanding of the present invention, they are deemed incorporated by reference herein.
  • Various combinations of polymer coating materials can be coordinated with biologically active species of interest to produce desired effects when coated on stents to be implanted in accordance with the invention. Loadings of therapeutic materials may vary. The mechanism of incorporation of the biologically active species into the surface coating, and egress mechanism depend both on the nature of the surface coating polymer and the material to be incorporated. The mechanism of release also depends on the mode of incorporation. The material may elute via interparticle paths or be administered via transport or diffusion through the encapsulating material itself.
  • For the purposes of this specification, “elution” is defined as any-process of release that involves extraction or release by direct contact of the material with bodily fluids through the interparticle paths connected with the exterior of the coating. “Transport” or “diffusion” are defined to include a mechanism of release in which a material released traverses through another material.
  • The desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material. The crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a crosslink structure of greater density will increase release time and reduce burst effect.
  • Additionally, with eluting materials such as heparin, release kinetics, particularly initial drug release rate, can be affected by varying the average dispersed particle size. The observed initial release rate or burst effect may be substantially reduced by using smaller particles, particularly if the particle size is controlled to be less than about 15 microns and the effect is even more significant in the particle size range of ≦10 microns, especially when the coating thickness is not more than about 50 μm and drug loading is about 25-45 weight percent.
  • It will also be appreciated that an unmedicated silicone thin top layer provides an advantage over drug containing top coat. Its surface has a limited porosity and is generally smooth, which may be less thrombogeneous and may reduce the chance to develop calcification, which occurs most often on the porous surface.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the drawings, wherein like numerals designate like parts throughout the same:
  • FIG. 1 is a schematic flow diagram illustrating the steps of the process of the invention;
  • FIG. 2 represents a release profile for a multi-layer system showing the percentage of heparin released over a two-week period;
  • FIG. 3 represents a release profile for a multi-layer system showing the relative release rate of heparin over a two-week period;
  • FIG. 4 illustrates a profile of release kinetics for different drug loadings at similar coating thicknesses illustrating the release of heparin over a two-week period;
  • FIG. 5 illustrates drug elution kinetics at a given loading of heparin over a two-week period at different coating thicknesses;
  • FIG. 6 illustrates the release kinetics in a coating having a given tie-layer thickness for different top coat thicknesses in which the percentage heparin in the tie coat and top coats are kept constant;
  • FIG. 7 illustrates the release kinetics of several coatings having an average coating thickness of 25 microns and a heparin loading of 37.5% but using four different average particle sizes;
  • FIGS. 8-11 are photomicrographs of coated stent fragments for the coatings of FIG. 7 having a corresponding average particle size of 4 microns, 17 microns, 22 microns and 30 microns, respectively.
  • DETAILED DESCRIPTION
  • According to the present invention, the stent coatings incorporating biologically active materials for timed delivery in situ in a body lumen of interest are preferably sprayed in many thin layers from prepared coating solutions or suspensions. The steps of the process are illustrated generally in FIG. 1. The coating solutions or suspensions are prepared at 10 as will be described later. The desired amount of crosslinking agent is added to the suspension/solution as at 12 and material is then agitated or stirred to produce a homogenous coating composition at 14 which is thereafter transferred to an application container or device which may be a container for spray painting at 16. Typical exemplary preparations of coating solutions that were used for heparin and dexamethasone appear next.
  • General Preparation of Heparin Coating Composition
  • Silicone was obtained as a polymer precursor in solvent (xylene) mixture. For example, a 35% solid silicone weight content in xylene was procured from Applied Silicone, Part #40,000. First, the silicone-xylene mixture was weighed. The solid silicone content was determined according to the vendor's analysis. Precalculated amounts of finely divided heparin (2-6 microns) were added into the silicone, then tetrahydrofuron (THF) HPCL grade (Aldrich or EM) was added. For a 37.5% heparin coating, for example: Wsilicone=5 g; solid percent=35%; Whep=5×0.35×0.375/(0.625)=1.05 g. The amount of THF needed (44 ml) in the coating solution was calculated by using the equation Wsilicone solid/VTHF=0.04 for a 37.5% heparin coating solution). Finally, the manufacturer crosslinker solution was added by using Pasteur P-pipet. The amount of crosslinker added was formed to effect the release rate profile. Typically, five drops of crosslinker solution were added for each five grams of silicone-xylene mixture. The crosslinker may be any suitable and compatible agent including platinum and peroxide based materials. The solution was stirred by using the stirring rod until the suspension was homogenous and milk-like. The coating solution was then transferred into a paint jar in condition for application by air brush.
  • General Preparation of Dexamethasone Coating Composition
  • Silicone (35% solution as above) was weighed into a beaker on a Metler balance. The weight of dexamethasone free alcohol or acetate form was calculated by silicone weight multiplied by 0.35 and the desired percentage of dexamethasone (1 to 40%) and the required amount was then weighed. Example: Wsilicone=5 g; for a 10% dexamethasone coating, Wdex=5×0.35×0.1/0.9=0.194 g and THF needed in the coating solution calculated. Wsilicone solid/VTHF=0.06 for a 10% dexamethasone coating solution. Example: Wsilicone=5 g; VTHF=5×0.35/0.06≈29 ml. The dexamethasone was weighed in a beaker on an analytical balance and half the total amount of THF was added. The solution was stirred well to ensure full dissolution of the dexamethasone. The stirred DEX-THF solution was then transferred to the silicone container. The beaker was washed with the remaining THF and this was transferred to the silicone container. The crosslinker was added by using a Pasteur pipet. Typically, five drops of crosslinker were used for five grams of silicone.
  • The application of the coating material to the stent was quite similar for all of the materials and the same for the heparin and dexamethasone suspensions prepared as in the above Examples. The suspension to be applied was transferred to an application device, typically a paint jar attached to an air brush, such as a Badger Model 150, supplied with a source of pressurized air through a regulator (Norgren, 0-160 psi). Once the brush hose was attached to the source of compressed air downstream of the regulator, the air was applied. The pressure was adjusted to approximately 15-25 psi and the nozzle condition checked by depressing the trigger.
  • Any appropriate method can be used to secure the stent for spraying and rotating fixtures were utilized successfully in the laboratory. Both ends of the relaxed stent were fastened to the fixture by two resilient retainers, commonly alligator clips, with the distance between the clips adjusted so that the stent remained in a relaxed, unstretched condition. The rotor was then energized and the spin speed adjusted to the desired coating speed, nominally about 40 rpm.
  • With the stent rotating in a substantially horizontal plane, the spray nozzle was adjusted so that the distance from the nozzle to the stent was about 2-4 inches and the composition was sprayed substantially horizontally with the brush being directed along the stent from the distal end of the stent to the proximal end and then from the proximal end to the distal end in a sweeping motion at a speed such that one spray cycle occurred in about three stent rotations. Typically a pause of less than one minute, normally about one-half minute, elapsed between layers. Of course, the number of coating layers did and will vary with the particular application. For example, for a coating level of 3-4 mg of heparin per cm2 of projected area, 20 cycles of coating application are required and about 30 ml of solution will be consumed for a 3.5 mm diameter by 14.5 cm long stent.
  • The rotation speed of the motor, of course, can be adjusted as can the viscosity of the composition and the flow rate of the spray nozzle as desired to modify the layered structure. Generally, with the above mixes, the best results have been obtained at rotational speeds in the range of 30-50 rpm and with a spray nozzle flow rate in the range of 4-10 ml of coating composition per minute, depending on the stent size. It is contemplated that a more sophisticated, computer-controlled coating apparatus will successfully automate the process demonstrated as feasible in the laboratory.
  • Several applied layers make up what is called the tie layer as at 18 and thereafter additional upper layers, which may be of a different composition with respect to bioactive material, the matrix polymeric materials and crosslinking agent, for example, are applied as the top layer as at 20. The application of the top layer follows the same coating procedure as the tie layer with the number and thickness of layers being optional. Of course, the thickness of any layer can be adjusted by modifying the speed of rotation of the stent and the spraying conditions. Generally, the total coating thickness is controlled by the number of spraying cycles or thin coats which make up the total coat.
  • As shown at 22 in FIG. 1, the coated stent is thereafter subjected to a curing step in which the pre-polymer and crosslinking agents cooperate to produce a cured polymer matrix containing the biologically active species. The curing process involves evaporation of the solvent xylene, THF, etc. and the curing and crosslinking of the polymer. Certain silicone materials can be cured at relatively low temperatures, (i.e. RT-50° C.) in what is known as a room temperature vulcanization (RTV) process. More typically, however, the curing process involves higher temperature curing materials and the coated stents are put into an oven at approximately 90° C. or higher for approximately 16 hours. The temperature may be raised to as high as 150° C. for dexamethasone containing coated stents. Of course, the time and temperature may vary with particular silicones, crosslinkers, and biologically active species.
  • Stents coated and cured in the manner described need to be sterilized prior to packaging for future implantation. For sterilization, gamma radiation is a preferred method particularly for heparin containing coatings; however, it has been found that stents coated and cured according to the process of the invention subjected to gamma sterilization may be too slow to recover their original posture when delivered to a vascular or other lumen site using a catheter unless a pretreatment step as at 24 is first applied to the coated, cured stent.
  • The pretreatment step involves an argon plasma treatment of the coated, cured stents in the unconstrained configuration. In accordance with this procedure, the stents are placed in a chamber of a plasma surface treatment system such as a Plasma Science 350 (Himont/Plasma Science, Foster City, Calif.). The system is equipped with a reactor chamber and RF solid-state generator operating at 13.56 mHz and from 0-500 watts power output and being equipped with a microprocessor controlled system and a complete vacuum pump package. The reaction chamber contains an unimpeded work volume of 16.75 inches (42.55 cm) by 13.5 inches (34.3 cm) by 17.5 inches (44.45 cm) in depth.
  • In the plasma process, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • After this, as shown at 26, the stents are exposed to gamma sterilization at 2.5-3.5 Mrad. The radiation may be carried out with the stent in either the radially non-constrained status—or in the radially constrained status.
  • With respect to the anticoagulant material heparin, the percentage in the tie layer is nominally from about 20-50% and that of the top layer from about 0-30% active material. The coating thickness ratio of the top layer to the tie layer varies from about 1:10 to 1:2 and is preferably in the range of from about 1:6 to 1:3.
  • Suppressing the burst effect also enables a reduction in the drug loading or in other words, allows a reduction in the coating thickness, since the physician will give a bolus injection of antiplatelet/anticoagulation drugs to the patient during the stenting process. As a result, the drug imbedded in the stent can be fully used without waste. Tailoring the first day release, but maximizing second day and third day release at the thinnest possible coating configuration will reduce the acute or subcute thrombosis.
  • FIG. 4 depicts the general effect of drug loading for coatings of similar thickness. The initial elution rate increases with the drug loading as shown in FIG. 5. The release rate also increases with the thickness of the coating at the same loading but tends to be inversely proportional to the thickness of the top layer as shown by the same drug loading and similar tie-coat thickness in FIG. 6.
  • The effect of average particle size is depicted in the FIGS. 7-11 in which coating layers with an average coating thickness of about 25 microns (μm), prepared and sterilized as above, were provided with dispersed heparin particles (to 37.5% heparin) of several different average particle sizes. FIG. 7 shows plots of elution kinetics for four different sizes of embedded heparin particles. The release took place in phosphate buffer (pH 7.4) at 37° C. The release rate using smaller, particularly 4-6 μm average sized particles noticeably reduces the initial rate or burst effect and thereafter the elution rate decreases more slowly with time. Average particle sizes above about 15 μm result in initial release rates approaching bolus elution. This, of course, is less desirable, both from the standpoint of being an unnecessary initial excess and for prematurely depleting the coating of deserved drug material.
  • In addition, as shown in the photomicrographs of FIGS. 8-11, as the average particle size increases, the morphology of the coating surface also changes coatings containing larger particles (FIGS. 9-11) have very rough and irregular surface characteristics. These surface irregularities may be more thrombogenic or exhibit an increased tendency to cause embolization when the corresponding stent is implanted in a blood vessel.
  • Accordingly, it has been found that the average particle size should generally be controlled below about 15 μm to reduce the burst effect and preferably should be ≦ about 10 μm for best results. The 4-6 μm size worked quite successfully in the laboratory. However, it should be noted that larger particle size can also be advantageously used, for instance, when the drug load is low, such as below 25 weight percent. Elution kinetics can be adjusted by a combination of changing the particle size and changing the load or concentration of the dispersed drug material.
  • What is apparent from the data gathered to date, however, is that the process of the present invention enables the drug elution kinetics to be modified to meet the needs of the particular stent application. In a similar manner, stent coatings can be prepared using a combination of two or more drugs and the drug release sequence and rate controlled. For example, antiproliferation drugs may be combined in the undercoat and anti-thrombotic drugs in the topcoat layer. In this manner, the anti-thrombotic drugs, for example, heparin, will elute first followed by antiproliferation drugs, e.g. dexamethasone, to better enable safe encapsulation of the implanted stent.
  • The heparin concentration measurement were made utilizing a standard curve prepared by complexing azure A dye with dilute solutions of heparin. Sixteen standards were used to compile the standard curve in a well-known manner.
  • For the elution test, the stents were immersed in a phosphate buffer solution at pH 7.4 in an incubator at approximately 37° C. Periodic samplings of the solution were processed to determine the amount of heparin eluted. After each sampling, each stent was placed in heparin-free buffer solution.
  • As stated above, while the allowable loading of the elastomeric material with heparin may vary, in the case of silicone materials heparin may exceed 60% of the total weight of the layer. However, the loading generally most advantageously used is in the range from about 10% to 45% of the total weight of the layer. In the case of dexamethasone, the loading may be as high as 50% or more of the total weight of the layer but is preferably in the range of about 0.4% to 45%.
  • It will be appreciated that the mechanism of incorporation of the biologically active species into a thin surface coating structure applicable to a metal stent is an important aspect of the present invention. The need for relatively thick-walled polymer elution stents or any membrane overlayers associated with many prior drug elution devices is obviated, as is the need for utilizing biodegradable or reabsorbable vehicles for carrying the biologically active species. The technique clearly enables long-term delivery and minimizes interference with the independent mechanical or therapeutic benefits of the stent itself.
  • Coating materials are designed with a particular coating technique, coating/drug combination and drug infusion mechanism in mind. Consideration of the particular form and mechanism of release of the biologically active species in the coating allow the technique to produce superior results. In this manner, delivery of the biologically active species from the coating structure can be tailored to accommodate a variety of applications.
  • Whereas the above examples depict-coatings having two different drug loadings or percentages of biologically active material to be released, this is by no means limiting with respect to the invention and it is contemplated that any number of layers and combinations of loadings can be employed to achieve a desired release profile. For example, gradual grading and change in the loading of the layers can be utilized in which, for example, higher loadings are used in the inner layers. Also layers can be used which have no drug loadings at all. For example, a pulsatile heparin release system may be achieved by a coating in which alternate layers containing heparin are sandwiched between unloaded layers of silicone or other materials for a portion of the coating. In other words, the invention allows untold numbers of combinations which result in a great deal of flexibility with respect to controlling the release of biologically active materials with regard to an implanted stent. Each applied layer is typically from approximately 0.5 microns to 15 microns in thickness. The total number of sprayed layers, of course, can vary widely, from less than 10 to more than 50 layers; commonly, 20 to 40 layers are included. The total thickness of the coating can also vary widely, but can generally be from about 10 to 200 microns.
  • Whereas the polymer of the coating may be any compatible biostable elastomeric material capable of being adhered to the stent material as a thin layer, hydrophobic materials are preferred because it has been found that the release of the biologically active species can generally be more predictably controlled with such materials. Preferred materials include silicone rubber elastomers and biostable polyurethanes specifically.
  • This invention has been described herein in considerable detail in order to comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principles and to construct and use embodiments of the example as required. However, it is to be understood that the invention can be carried out by specifically different devices and that various modifications can be accomplished without departing from the scope of the invention itself.

Claims (21)

1-23. (canceled)
24. An implantable medical device having an outer surface, covered at least in part by a conformal coating comprising an undercoat of a hydrophobic biostable elastomeric material which does not degrade, and incorporates an amount of a biologically active material therein for timed delivery therefrom;
and a topcoat comprising a polymeric material, which at least partially covers the undercoat,
wherein the undercoat and the topcoat are of different formulations.
25. The medical device of claim 24, wherein the medical device is a stent for vascular implantation.
26. The medical device of claim 25, wherein the stent is expandable.
27. The medical device of claim 25, wherein the stent comprises a tubular body having open ends and an open lattice sidewall structure and wherein said coating conforms to said sidewall structure in a manner that preserves said open lattice.
28. The medical device of claim 25, wherein the stent comprises stainless steel.
29. The medical device of claim 24, wherein the undercoat comprises an ethylene vinyl acetate copolymer.
30. The medical device of claim 24, wherein most or all of the biologically active material is contained in the undercoat.
31. The medical device of claim 24, wherein the topcoat consists of the polymeric material.
32. The medical device of claim 24, wherein the biologically active material is an antibiotic.
33. A method of making the medical device of claim 24, wherein said method comprises the steps of:
(a) applying an undercoat of a formulation containing uncured hydrophobic elastomeric material in solvent mixture and an amount of the biologically active material that is finely divided;
(b) curing said hydrophobic elastomeric material; and
(c) applying a topcoat of a formulation comprising the polymeric material to form the topcoat.
34. A method of coating an implantable prosthesis with a first polymeric material incorporating an amount of biologically active material therein for timed delivery therefrom comprising the steps of:
(a) applying a first formulation comprising the first polymeric material and the biologically active material to a surface of the prosthesis to form an under layer when the biologically active material is particulate;
(b) applying a second formulation comprising a second polymeric material over the under layer to form a top layer; and
(c) curing the first and second polymeric materials, wherein the first polymeric material is a hydrophobic elastomeric material, the average particle size of the biologically active material in the first formulation is less than or equal to about 15 μm and at least some of the biologically active material is particulate after curing, whereby the first and second formulations are applied to the prosthesis in a manner to adheringly conform thereto.
35. The method of claim 34 wherein the elastomeric material is selected from the group consisting of silicones, polyurethanes, polyamide elastomers, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and combinations thereof.
36. The method of claim 34, wherein the first formulation comprises about 25-45 weight percent of the biologically active material includes heparin.
37. The method of claim 34, wherein the biologically active material has an average particle size less than or equal to about 10 μm before curing.
38. The method of claim 34, wherein the biologically active material includes heparin.
39. The method of any one of claim 34, wherein the implantable prosthesis is an expandable stent having a tubular metal body with a surface of an open lattice nature having openings therein, and wherein the first and second formulations are applied with the stent expanded.
40. The method of claim 39 wherein the expandable stent is a self-expanding stent.
41. The method of claim 34 wherein the second formulation is substantially free of any biologically active material.
42. The method of claim 34 wherein the second formulation is substantially free of the biologically active material in the first formulation.
43. The method of claim 34 wherein the under layer and the top layer each have a thickness and the ratio of the thickness of the top layer to the thickness of the under layer is from about 1:10 to 1:2.
US10/989,946 1995-04-19 2004-11-16 Medical device with drug Abandoned US20050106210A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/989,946 US20050106210A1 (en) 1995-04-19 2004-11-16 Medical device with drug

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42488495A 1995-04-19 1995-04-19
US52627395A 1995-09-11 1995-09-11
US08/663,490 US5837313A (en) 1995-04-19 1996-06-13 Drug release stent coating process
US08/663,518 US6120536A (en) 1995-04-19 1996-06-13 Medical devices with long term non-thrombogenic coatings
US09/012,443 US6358556B1 (en) 1995-04-19 1998-01-23 Drug release stent coating
US10/067,041 US20020071902A1 (en) 1995-04-19 2002-02-04 Drug release stent coating
US10/989,946 US20050106210A1 (en) 1995-04-19 2004-11-16 Medical device with drug

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/067,041 Continuation US20020071902A1 (en) 1995-04-19 2002-02-04 Drug release stent coating

Publications (1)

Publication Number Publication Date
US20050106210A1 true US20050106210A1 (en) 2005-05-19

Family

ID=27062077

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/663,490 Expired - Lifetime US5837313A (en) 1995-04-19 1996-06-13 Drug release stent coating process
US09/012,443 Expired - Lifetime US6358556B1 (en) 1995-04-19 1998-01-23 Drug release stent coating
US10/067,041 Abandoned US20020071902A1 (en) 1995-04-19 2002-02-04 Drug release stent coating
US10/989,946 Abandoned US20050106210A1 (en) 1995-04-19 2004-11-16 Medical device with drug

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/663,490 Expired - Lifetime US5837313A (en) 1995-04-19 1996-06-13 Drug release stent coating process
US09/012,443 Expired - Lifetime US6358556B1 (en) 1995-04-19 1998-01-23 Drug release stent coating
US10/067,041 Abandoned US20020071902A1 (en) 1995-04-19 2002-02-04 Drug release stent coating

Country Status (14)

Country Link
US (4) US5837313A (en)
EP (6) EP1500407B1 (en)
JP (1) JPH11500047A (en)
KR (1) KR19990044571A (en)
AT (2) ATE376431T1 (en)
AU (1) AU703805B2 (en)
BR (1) BR9610607A (en)
CA (1) CA2231727C (en)
DE (2) DE69637302T2 (en)
ES (1) ES2295995T3 (en)
IL (1) IL123622A (en)
NO (1) NO981066L (en)
WO (1) WO1997010011A1 (en)
ZA (1) ZA967625B (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040098117A1 (en) * 2001-06-29 2004-05-20 Hossainy Syed F.A. Composite stent with regioselective material and a method of forming the same
US20040238978A1 (en) * 2002-09-20 2004-12-02 Diaz Stephen Hunter Method and apparatus for loading a benefical agent into an expandable medical device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050287287A1 (en) * 2004-06-24 2005-12-29 Parker Theodore L Methods and systems for loading an implantable medical device with beneficial agent
US20060122697A1 (en) * 2002-09-20 2006-06-08 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
US20080033522A1 (en) * 2006-08-03 2008-02-07 Med Institute, Inc. Implantable Medical Device with Particulate Coating
US20080097588A1 (en) * 2006-10-18 2008-04-24 Conor Medsystems, Inc. Systems and Methods for Producing a Medical Device
US20080195079A1 (en) * 2007-02-07 2008-08-14 Cook Incorporated Medical device coatings for releasing a therapeutic agent at multiple rates
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7691401B2 (en) 2000-09-28 2010-04-06 Advanced Cardiovascular Systems, Inc. Poly(butylmethacrylate) and rapamycin coated stent
US7713637B2 (en) 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7775178B2 (en) 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US8029816B2 (en) 2006-06-09 2011-10-04 Abbott Cardiovascular Systems Inc. Medical device coated with a coating containing elastin pentapeptide VGVPG
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8062350B2 (en) 2006-06-14 2011-11-22 Abbott Cardiovascular Systems Inc. RGD peptide attached to bioabsorbable stents
US8067025B2 (en) 2006-02-17 2011-11-29 Advanced Cardiovascular Systems, Inc. Nitric oxide generating medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US8147769B1 (en) * 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US8173199B2 (en) 2002-03-27 2012-05-08 Advanced Cardiovascular Systems, Inc. 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8303609B2 (en) 2000-09-29 2012-11-06 Cordis Corporation Coated medical devices
US8304012B2 (en) 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US8568764B2 (en) 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8586069B2 (en) 2002-12-16 2013-11-19 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US8597673B2 (en) 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US9682162B2 (en) 2006-08-15 2017-06-20 Abbott Cardiovascular Systems Inc. Sterilization methods for medical devices

Families Citing this family (817)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682608B2 (en) * 1990-12-18 2004-01-27 Advanced Cardiovascular Systems, Inc. Superelastic guiding member
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
EP0650740B1 (en) * 1993-10-27 1999-09-22 Schneider (Europe) GmbH Interventional catheter
US6659977B2 (en) 1993-10-27 2003-12-09 Schneider (Europe) A.G. Multilayer interventional catheter
US5961765A (en) * 1994-09-20 1999-10-05 Schneider (Europe) A. G. Method of making a catheter
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
ATE229356T1 (en) 1996-04-26 2002-12-15 Schneider Europ Gmbh INTERVENTION CATHETER
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US7686846B2 (en) * 1996-06-06 2010-03-30 Devax, Inc. Bifurcation stent and method of positioning in a body lumen
US7238197B2 (en) * 2000-05-30 2007-07-03 Devax, Inc. Endoprosthesis deployment system for treating vascular bifurcations
US8728143B2 (en) * 1996-06-06 2014-05-20 Biosensors International Group, Ltd. Endoprosthesis deployment system for treating vascular bifurcations
US5928279A (en) * 1996-07-03 1999-07-27 Baxter International Inc. Stented, radially expandable, tubular PTFE grafts
IT1289815B1 (en) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS
US6240616B1 (en) 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US8172897B2 (en) 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
US8790391B2 (en) 1997-04-18 2014-07-29 Cordis Corporation Methods and devices for delivering therapeutic agents to target vessels
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US6165166A (en) 1997-04-25 2000-12-26 Schneider (Usa) Inc. Trilayer, extruded medical tubing and medical devices incorporating such tubing
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6056993A (en) * 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6203536B1 (en) 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US5899935A (en) * 1997-08-04 1999-05-04 Schneider (Usa) Inc. Balloon expandable braided stent with restraint
US5897911A (en) * 1997-08-11 1999-04-27 Advanced Cardiovascular Systems, Inc. Polymer-coated stent structure
AU8782098A (en) * 1997-08-13 1999-03-08 Boston Scientific Limited Loading and release of water-insoluble drugs
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7445792B2 (en) * 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20050171478A1 (en) * 1998-01-13 2005-08-04 Selmon Matthew R. Catheter system for crossing total occlusions in vasculature
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US20070087028A1 (en) * 1998-04-16 2007-04-19 Robert Falotico Intraluminal devices for the prevention and treatment of vascular disease
ES2179646T3 (en) * 1998-04-27 2003-01-16 Surmodics Inc COATING THAT RELEASES A BIOACTIVE AGENT.
US6013099A (en) 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
EP1112095B1 (en) 1998-09-11 2002-11-20 Gerhard Dr. Schmidmaier Biologically active implants
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US20020007145A1 (en) 1998-10-23 2002-01-17 Timothy Stivland Catheter having improved bonding region
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6955661B1 (en) * 1999-01-25 2005-10-18 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US7572245B2 (en) * 2003-09-15 2009-08-11 Atrium Medical Corporation Application of a therapeutic substance to a tissue location using an expandable medical device
US7947015B2 (en) 1999-01-25 2011-05-24 Atrium Medical Corporation Application of a therapeutic substance to a tissue location using an expandable medical device
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6767418B1 (en) * 1999-04-23 2004-07-27 Terumo Kabushiki Kaisha Ti-Zr type alloy and medical appliance formed thereof
DE19921088C2 (en) * 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent to keep aisle-like structures open
US6290673B1 (en) * 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6610035B2 (en) 1999-05-21 2003-08-26 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hybrid top coat
US6176849B1 (en) 1999-05-21 2001-01-23 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hydrophobic top coat
US20030070676A1 (en) * 1999-08-05 2003-04-17 Cooper Joel D. Conduits having distal cage structure for maintaining collateral channels in tissue and related methods
US6273901B1 (en) * 1999-08-10 2001-08-14 Scimed Life Systems, Inc. Thrombosis filter having a surface treatment
US6485735B1 (en) * 1999-08-31 2002-11-26 Phelps Dodge High Performance Conductors Of Sc & Ga, Inc. Multilayer thermoset polymer matrix and structures made therefrom
US6503556B2 (en) 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20040029952A1 (en) * 1999-09-03 2004-02-12 Yung-Ming Chen Ethylene vinyl alcohol composition and coating
US7682647B2 (en) 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
US6759054B2 (en) 1999-09-03 2004-07-06 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol composition and coating
US6749626B1 (en) 2000-03-31 2004-06-15 Advanced Cardiovascular Systems, Inc. Actinomycin D for the treatment of vascular disease
US6503954B1 (en) 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6713119B2 (en) 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US6254631B1 (en) * 1999-09-23 2001-07-03 Intratherapeutics, Inc. Stent with enhanced friction
US6458867B1 (en) 1999-09-28 2002-10-01 Scimed Life Systems, Inc. Hydrophilic lubricant coatings for medical devices
WO2001039695A2 (en) * 1999-12-01 2001-06-07 Advanced Cardiovascular Systems, Inc. Nitinol alloy composition for vascular stents
US6602287B1 (en) 1999-12-08 2003-08-05 Advanced Cardiovascular Systems, Inc. Stent with anti-thrombogenic coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) * 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6908624B2 (en) * 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
WO2001047572A2 (en) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US7604663B1 (en) 1999-12-30 2009-10-20 St. Jude Medical, Inc. Medical devices with polymer/inorganic substrate composites
AU2001229631A1 (en) * 2000-01-19 2001-07-31 Johns Hopkins University Method and apparatus for coating an endoprosthesis
US7621947B2 (en) * 2000-03-01 2009-11-24 Medinol, Ltd. Longitudinally flexible stent
US6723119B2 (en) * 2000-03-01 2004-04-20 Medinol Ltd. Longitudinally flexible stent
US7828835B2 (en) * 2000-03-01 2010-11-09 Medinol Ltd. Longitudinally flexible stent
US7758627B2 (en) * 2000-03-01 2010-07-20 Medinol, Ltd. Longitudinally flexible stent
US8920487B1 (en) 2000-03-01 2014-12-30 Medinol Ltd. Longitudinally flexible stent
US8496699B2 (en) * 2000-03-01 2013-07-30 Medinol Ltd. Longitudinally flexible stent
US8202312B2 (en) * 2000-03-01 2012-06-19 Medinol Ltd. Longitudinally flexible stent
US7141062B1 (en) * 2000-03-01 2006-11-28 Medinol, Ltd. Longitudinally flexible stent
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US20040086420A1 (en) * 2000-03-23 2004-05-06 Macphee Martin J. Methods for sterilizing serum or plasma
US6818247B1 (en) 2000-03-31 2004-11-16 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent
US8109994B2 (en) 2003-01-10 2012-02-07 Abbott Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US7875283B2 (en) 2000-04-13 2011-01-25 Advanced Cardiovascular Systems, Inc. Biodegradable polymers for use with implantable medical devices
US6527801B1 (en) 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US7013182B1 (en) * 2000-05-04 2006-03-14 Cardiac Pacemakers, Inc. Conductive polymer sheath on defibrillator shocking coils
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20020007215A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020007214A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
AU2001261625B2 (en) 2000-05-16 2006-04-06 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US20030139803A1 (en) * 2000-05-30 2003-07-24 Jacques Sequin Method of stenting a vessel with stent lumenal diameter increasing distally
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US20040211362A1 (en) * 2000-05-31 2004-10-28 Daniel Castro System for coating a stent
US7682648B1 (en) 2000-05-31 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for forming polymeric coatings on stents
US6723373B1 (en) * 2000-06-16 2004-04-20 Cordis Corporation Device and process for coating stents
US6451373B1 (en) 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
DE60118933T2 (en) 2000-08-15 2006-11-30 SurModics, Inc., Eden Prairie MATRIX FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
ES2312456T3 (en) 2000-08-30 2009-03-01 Johns Hopkins University DEVICES FOR INTRAOCULAR SUPPLY OF PHARMACOS.
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6746773B2 (en) * 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20070276474A1 (en) * 2000-09-29 2007-11-29 Llanos Gerard H Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20050226993A1 (en) * 2000-10-03 2005-10-13 Nawrocki Jesse G Medical devices having durable and lubricious polymeric coating
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
DK1328213T3 (en) 2000-10-16 2005-11-28 Conor Medsystems Inc Expandable medical device for delivery of a useful agent
US6833153B1 (en) 2000-10-31 2004-12-21 Advanced Cardiovascular Systems, Inc. Hemocompatible coatings on hydrophobic porous polymers
US7807210B1 (en) * 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US20100125329A1 (en) * 2000-11-02 2010-05-20 Zhi Cheng Lin Pseudoelastic stents having a drug coating and a method of producing the same
US7976648B1 (en) 2000-11-02 2011-07-12 Abbott Cardiovascular Systems Inc. Heat treatment for cold worked nitinol to impart a shape setting capability without eventually developing stress-induced martensite
US6602272B2 (en) 2000-11-02 2003-08-05 Advanced Cardiovascular Systems, Inc. Devices configured from heat shaped, strain hardened nickel-titanium
US9107605B2 (en) * 2000-11-17 2015-08-18 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Device for in vivo delivery of bioactive agents and method of manufacture thereof
US10398830B2 (en) * 2000-11-17 2019-09-03 Vactronix Scientific, Llc Device for in vivo delivery of bioactive agents and method of manufacture thereof
WO2002041931A2 (en) * 2000-11-27 2002-05-30 Medtronic, Inc. Stents and methods for preparing stents
US7498042B2 (en) 2000-11-30 2009-03-03 Kyoto Medical Planning Co., Ltd. Stent for blood vessel and material for stent for blood vessel
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US6855161B2 (en) 2000-12-27 2005-02-15 Advanced Cardiovascular Systems, Inc. Radiopaque nitinol alloys for medical devices
US6540776B2 (en) 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
US7504125B1 (en) 2001-04-27 2009-03-17 Advanced Cardiovascular Systems, Inc. System and method for coating implantable devices
US6547812B1 (en) 2000-12-29 2003-04-15 Advanced Cardiovascular Systems, Inc. Radiation therapy using a radioactive implantable device and a radiosensitizer agent
DE10144144B4 (en) * 2001-01-02 2004-12-30 Rehau Ag + Co Process for the manufacture of a stent with a polymeric covering
US20030215564A1 (en) * 2001-01-18 2003-11-20 Heller Phillip F. Method and apparatus for coating an endoprosthesis
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
DE10105592A1 (en) 2001-02-06 2002-08-08 Achim Goepferich Placeholder for drug release in the frontal sinus
WO2002065946A1 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Apparatus for loading a therapeutic agent onto an endovascular device
US6682695B2 (en) * 2001-03-23 2004-01-27 Clearant, Inc. Methods for sterilizing biological materials by multiple rates
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
SK287686B6 (en) * 2001-04-10 2011-06-06 Ciba Specialty Chemicals Holding Inc. Stabilized medium and high voltage cable insulation composition and a method for the production thereof
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US6712845B2 (en) 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
EP1383504A1 (en) * 2001-04-26 2004-01-28 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US6656506B1 (en) 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7666462B2 (en) * 2001-05-11 2010-02-23 Exogenesis Corporation Method of controlling a drug release rate
US7105199B2 (en) * 2001-05-11 2006-09-12 Exogenesis Corporation Methods of adhering drugs to the surface of medical devices through ion beam surface modification
US7923055B2 (en) 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
US6685745B2 (en) * 2001-05-15 2004-02-03 Scimed Life Systems, Inc. Delivering an agent to a patient's body
US7247338B2 (en) 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US7651695B2 (en) 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
US6743462B1 (en) * 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7363091B1 (en) * 2001-07-11 2008-04-22 Pacesetter Inc. Method of molding silicone elastomer drug carrier in an endocardial lead
US7246321B2 (en) * 2001-07-13 2007-07-17 Anoto Ab Editing data
US6692772B2 (en) * 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
EP1406590B1 (en) * 2001-07-19 2005-04-27 Veritas AG Method for producing articles consisting of polymer materials having a medicamentous depot effect
WO2003009773A2 (en) 2001-07-26 2003-02-06 Alveolus Inc. Removable stent and method of using the same
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US20030031584A1 (en) * 2001-08-10 2003-02-13 Wilson Burgess Methods for sterilizing biological materials using dipeptide stabilizers
US6946098B2 (en) 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US7708712B2 (en) 2001-09-04 2010-05-04 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
US8303651B1 (en) * 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7989018B2 (en) 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7285304B1 (en) * 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US20030060873A1 (en) * 2001-09-19 2003-03-27 Nanomedical Technologies, Inc. Metallic structures incorporating bioactive materials and methods for creating the same
US6863683B2 (en) 2001-09-19 2005-03-08 Abbott Laboratoris Vascular Entities Limited Cold-molding process for loading a stent onto a stent delivery system
US7776379B2 (en) * 2001-09-19 2010-08-17 Medlogics Device Corporation Metallic structures incorporating bioactive materials and methods for creating the same
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030095890A1 (en) * 2001-09-24 2003-05-22 Shirley Miekka Methods for sterilizing biological materials containing non-aqueous solvents
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
AU2002336761A1 (en) * 2001-09-26 2003-04-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Nitric oxide-releasing coated medical devices and method of preparing same
US7223282B1 (en) * 2001-09-27 2007-05-29 Advanced Cardiovascular Systems, Inc. Remote activation of an implantable device
US20030059520A1 (en) 2001-09-27 2003-03-27 Yung-Ming Chen Apparatus for regulating temperature of a composition and a method of coating implantable devices
US6753071B1 (en) 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
DE60235775D1 (en) * 2001-11-08 2010-05-06 Ziscoat N V Intraluminal device with a therapeutic agent-containing coating
US7585516B2 (en) 2001-11-12 2009-09-08 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices
US20060292206A1 (en) 2001-11-26 2006-12-28 Kim Steven W Devices and methods for treatment of vascular aneurysms
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US7175874B1 (en) 2001-11-30 2007-02-13 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US20030114919A1 (en) * 2001-12-10 2003-06-19 Mcquiston Jesse Polymeric stent with metallic rings
CN1303947C (en) * 2001-12-13 2007-03-14 华东理工大学 Medicine eluted cardiovascular frame and its preparing process
US20030124023A1 (en) * 2001-12-21 2003-07-03 Wilson Burgess Method of sterilizing heart valves
AU2002360712A1 (en) * 2001-12-21 2003-07-30 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US6866805B2 (en) 2001-12-27 2005-03-15 Advanced Cardiovascular Systems, Inc. Hybrid intravascular stent
US7201771B2 (en) 2001-12-27 2007-04-10 Arbor Surgical Technologies, Inc. Bioprosthetic heart valve
US6709514B1 (en) * 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US7105198B2 (en) * 2002-01-14 2006-09-12 Medtronic Vascular, Inc. Method for coating stent
US20030180181A1 (en) * 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
JP3993773B2 (en) * 2002-02-20 2007-10-17 株式会社日立製作所 Storage subsystem, storage control device, and data copy method
JP4575667B2 (en) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Macrocyclic compounds useful as pharmaceuticals
US20030207856A1 (en) * 2002-03-18 2003-11-06 Patrice Tremble Medical devices and compositions for delivering anti-proliferatives to anatomical sites at risk for restenosis
US7022334B1 (en) * 2002-03-20 2006-04-04 Advanced Cardiovascular Systems, Inc. Therapeutic composition and a method of coating implantable medical devices
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
EP2374454B1 (en) 2002-03-22 2016-05-11 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
AU2003226770A1 (en) * 2002-03-27 2003-10-08 Galen (Chemicals) Limited Intravaginal reservoir drug delivery devices
US7691461B1 (en) 2002-04-01 2010-04-06 Advanced Cardiovascular Systems, Inc. Hybrid stent and method of making
US20030195610A1 (en) * 2002-04-04 2003-10-16 Herrmann Robert A. Processes for producing polymer coatings through surface polymerization
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20040230288A1 (en) * 2002-04-17 2004-11-18 Rosenthal Arthur L. Medical devices adapted for controlled in vivo structural change after implantation
US20030204168A1 (en) * 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US7122048B2 (en) * 2002-05-03 2006-10-17 Scimed Life Systems, Inc. Hypotube endoluminal device
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20030232087A1 (en) * 2002-06-18 2003-12-18 Lawin Laurie R. Bioactive agent release coating with aromatic poly(meth)acrylates
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7959674B2 (en) * 2002-07-16 2011-06-14 Medtronic, Inc. Suture locking assembly and method of use
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US20040013562A1 (en) * 2002-07-18 2004-01-22 Wilson Burgess Methods for sterilizing milk.
US7294329B1 (en) * 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US6908591B2 (en) * 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
US6761734B2 (en) 2002-07-22 2004-07-13 William S. Suhr Segmented balloon catheter for stenting bifurcation lesions
US20050008828A1 (en) * 2002-07-25 2005-01-13 Trustees Of Stevens Institute Of Technology Patterned polymer microgel and method of forming same
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US20040024448A1 (en) 2002-08-05 2004-02-05 Chang James W. Thermoplastic fluoropolymer-coated medical devices
WO2004014447A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a poly(ethylene-co-(meth)acrylate), medical device, and method
JP2006502136A (en) * 2002-08-13 2006-01-19 メドトロニック・インコーポレーテッド Active agent delivery system comprising a hydrophilic polymer, a medical device, and a method
CA2494188A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a hydrophobic cellulose derivative
AU2003258209A1 (en) * 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
CA2494187A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a polyurethane, medical device, and method
US7363074B1 (en) * 2002-08-20 2008-04-22 Advanced Cardiovascular Systems, Inc. Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
US7732535B2 (en) * 2002-09-05 2010-06-08 Advanced Cardiovascular Systems, Inc. Coating for controlled release of drugs from implantable medical devices
US20040054104A1 (en) * 2002-09-05 2004-03-18 Pacetti Stephen D. Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
AU2003218077B2 (en) * 2002-09-06 2009-10-08 Abbott Laboratories Medical device having hydration inhibitor
US7201935B1 (en) 2002-09-17 2007-04-10 Advanced Cardiovascular Systems, Inc. Plasma-generated coatings for medical devices and methods for fabricating thereof
US7438722B1 (en) 2002-09-20 2008-10-21 Advanced Cardiovascular Systems, Inc. Method for treatment of restenosis
US20040059409A1 (en) * 2002-09-24 2004-03-25 Stenzel Eric B. Method of applying coatings to a medical device
US7396538B2 (en) * 2002-09-26 2008-07-08 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7125577B2 (en) * 2002-09-27 2006-10-24 Surmodics, Inc Method and apparatus for coating of substrates
US20060100695A1 (en) * 2002-09-27 2006-05-11 Peacock James C Iii Implantable stent with modified ends
US8202530B2 (en) * 2002-09-27 2012-06-19 Advanced Cardiovascular Systems, Inc. Biocompatible coatings for stents
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US7192484B2 (en) 2002-09-27 2007-03-20 Surmodics, Inc. Advanced coating apparatus and method
US7404979B1 (en) 2002-09-30 2008-07-29 Advanced Cardiovascular Systems Inc. Spin coating apparatus and a method for coating implantable devices
US6770729B2 (en) * 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US8337937B2 (en) * 2002-09-30 2012-12-25 Abbott Cardiovascular Systems Inc. Stent spin coating method
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7041088B2 (en) * 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
US20040093056A1 (en) 2002-10-26 2004-05-13 Johnson Lianw M. Medical appliance delivery apparatus and method of use
US7637942B2 (en) 2002-11-05 2009-12-29 Merit Medical Systems, Inc. Coated stent with geometry determinated functionality and method of making the same
US7959671B2 (en) 2002-11-05 2011-06-14 Merit Medical Systems, Inc. Differential covering and coating methods
US7527644B2 (en) 2002-11-05 2009-05-05 Alveolus Inc. Stent with geometry determinated functionality and method of making the same
US7875068B2 (en) 2002-11-05 2011-01-25 Merit Medical Systems, Inc. Removable biliary stent
AU2003290675A1 (en) * 2002-11-07 2004-06-03 Abbott Laboratories Method of loading beneficial agent to a prosthesis by fluid-jet application
US8221495B2 (en) 2002-11-07 2012-07-17 Abbott Laboratories Integration of therapeutic agent into a bioerodible medical device
US8524148B2 (en) * 2002-11-07 2013-09-03 Abbott Laboratories Method of integrating therapeutic agent into a bioerodible medical device
US20040148016A1 (en) * 2002-11-07 2004-07-29 Klein Dean A. Biocompatible medical device coatings
US20040142014A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
EP1567087B1 (en) 2002-11-08 2009-04-01 Jacques Seguin Endoprosthesis for vascular bifurcation
KR20050086440A (en) * 2002-11-08 2005-08-30 코너 메드시스템즈, 인코포레이티드 Method and apparatus for reducing tissue damage after ischemic injury
US20040143321A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US8034361B2 (en) * 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
US7481821B2 (en) 2002-11-12 2009-01-27 Thomas J. Fogarty Embolization device and a method of using the same
US7022372B1 (en) 2002-11-12 2006-04-04 Advanced Cardiovascular Systems, Inc. Compositions for coating implantable medical devices
US6896965B1 (en) 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US6982004B1 (en) 2002-11-26 2006-01-03 Advanced Cardiovascular Systems, Inc. Electrostatic loading of drugs on implantable medical devices
US7211150B1 (en) * 2002-12-09 2007-05-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating and drying multiple stents
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) * 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) * 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US7338557B1 (en) * 2002-12-17 2008-03-04 Advanced Cardiovascular Systems, Inc. Nozzle for use in coating a stent
US8551162B2 (en) 2002-12-20 2013-10-08 Medtronic, Inc. Biologically implantable prosthesis
US7846198B2 (en) * 2002-12-24 2010-12-07 Novostent Corporation Vascular prosthesis and methods of use
US7455687B2 (en) * 2002-12-30 2008-11-25 Advanced Cardiovascular Systems, Inc. Polymer link hybrid stent
US20040236415A1 (en) * 2003-01-02 2004-11-25 Richard Thomas Medical devices having drug releasing polymer reservoirs
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20040260382A1 (en) 2003-02-12 2004-12-23 Fogarty Thomas J. Intravascular implants and methods of using the same
US7087115B1 (en) * 2003-02-13 2006-08-08 Advanced Cardiovascular Systems, Inc. Nozzle and method for use in coating a stent
US20040167572A1 (en) * 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
ATE485847T1 (en) * 2003-02-21 2010-11-15 Sorin Biomedica Cardio Srl METHOD FOR PRODUCING A STENT AND CORRESPONDING STENT
US7255891B1 (en) * 2003-02-26 2007-08-14 Advanced Cardiovascular Systems, Inc. Method for coating implantable medical devices
US6926919B1 (en) 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US8715771B2 (en) * 2003-02-26 2014-05-06 Abbott Cardiovascular Systems Inc. Coated stent and method of making the same
US7563483B2 (en) 2003-02-26 2009-07-21 Advanced Cardiovascular Systems Inc. Methods for fabricating a coating for implantable medical devices
US7063884B2 (en) 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US7025779B2 (en) 2003-02-26 2006-04-11 Scimed Life Systems, Inc. Endoluminal device having enhanced affixation characteristics
US7288609B1 (en) * 2003-03-04 2007-10-30 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices based on poly (orthoesters)
EP1462801A3 (en) * 2003-03-24 2005-01-05 Tepnel Lifecodes Methods for determining the negative control value for multi-analyte assays
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
US7527632B2 (en) * 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
US7637934B2 (en) 2003-03-31 2009-12-29 Merit Medical Systems, Inc. Medical appliance optical delivery and deployment apparatus and method
US20040243224A1 (en) * 2003-04-03 2004-12-02 Medtronic Vascular, Inc. Methods and compositions for inhibiting narrowing in mammalian vascular pathways
US7241455B2 (en) 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
US8791171B2 (en) 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
US7942892B2 (en) * 2003-05-01 2011-05-17 Abbott Cardiovascular Systems Inc. Radiopaque nitinol embolic protection frame
US7563454B1 (en) * 2003-05-01 2009-07-21 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
AU2004237774B2 (en) 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7323209B1 (en) 2003-05-15 2008-01-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating stents
US20040236416A1 (en) * 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
DE10329260A1 (en) * 2003-06-23 2005-01-13 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Stent with a coating system
US7341630B1 (en) * 2003-06-26 2008-03-11 Advanced Cardiovascular Systems, Inc. Stent coating system
US7645504B1 (en) 2003-06-26 2010-01-12 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
US7431733B2 (en) * 2003-06-27 2008-10-07 University Of South Florida Vascular prosthesis
US7077922B2 (en) * 2003-07-02 2006-07-18 Owens Corning Composites S.P.R.L. Technique to fill silencers
US7318945B2 (en) 2003-07-09 2008-01-15 Medtronic Vascular, Inc. Laminated drug-polymer coated stent having dipped layers
US7875285B1 (en) 2003-07-15 2011-01-25 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices having controlled rate of release
US20050015110A1 (en) * 2003-07-18 2005-01-20 Fogarty Thomas J. Embolization device and a method of using the same
WO2005006963A2 (en) 2003-07-18 2005-01-27 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
US8308682B2 (en) 2003-07-18 2012-11-13 Broncus Medical Inc. Devices for maintaining patency of surgically created channels in tissue
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US20060014003A1 (en) * 2003-07-24 2006-01-19 Libera Matthew R Functional nano-scale gels
US7169404B2 (en) 2003-07-30 2007-01-30 Advanced Cardiovasular Systems, Inc. Biologically absorbable coatings for implantable devices and methods for fabricating the same
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US9114199B2 (en) * 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US8870814B2 (en) * 2003-07-31 2014-10-28 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agent
US7914805B2 (en) * 2003-07-31 2011-03-29 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US7645474B1 (en) 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US7431959B1 (en) * 2003-07-31 2008-10-07 Advanced Cardiovascular Systems Inc. Method and system for irradiation of a drug eluting implantable medical device
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
CA2535346A1 (en) * 2003-08-13 2005-03-03 Medtronic, Inc. Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
US20050064005A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
US8021421B2 (en) 2003-08-22 2011-09-20 Medtronic, Inc. Prosthesis heart valve fixturing device
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
US8021331B2 (en) * 2003-09-15 2011-09-20 Atrium Medical Corporation Method of coating a folded medical device
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8801692B2 (en) * 2003-09-24 2014-08-12 Medtronic Vascular, Inc. Gradient coated stent and method of fabrication
US7441513B1 (en) 2003-09-26 2008-10-28 Advanced Cardiovascular Systems, Inc. Plasma-generated coating apparatus for medical devices and a method of coating deposition
US7744645B2 (en) * 2003-09-29 2010-06-29 Medtronic Vascular, Inc. Laminated drug-polymer coated stent with dipped and cured layers
US7318932B2 (en) 2003-09-30 2008-01-15 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
JP2007514518A (en) * 2003-10-02 2007-06-07 トラスティーズ オブ スティーヴンス インスティチュート オブ テクノロジー Capsule of multilayer neutral polymer film bonded by hydrogen bonding
US7704544B2 (en) 2003-10-07 2010-04-27 Advanced Cardiovascular Systems, Inc. System and method for coating a tubular implantable medical device
US7556647B2 (en) 2003-10-08 2009-07-07 Arbor Surgical Technologies, Inc. Attachment device and methods of using the same
US7208172B2 (en) * 2003-11-03 2007-04-24 Medlogics Device Corporation Metallic composite coating for delivery of therapeutic agents from the surface of implantable devices
US7329413B1 (en) 2003-11-06 2008-02-12 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
US7261946B2 (en) * 2003-11-14 2007-08-28 Advanced Cardiovascular Systems, Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7560492B1 (en) 2003-11-25 2009-07-14 Advanced Cardiovascular Systems, Inc. Polysulfone block copolymers as drug-eluting coating material
US7807722B2 (en) 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
US20050119723A1 (en) * 2003-11-28 2005-06-02 Medlogics Device Corporation Medical device with porous surface containing bioerodable bioactive composites and related methods
US7220816B2 (en) 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US20050137677A1 (en) * 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050149174A1 (en) * 2003-12-18 2005-07-07 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20050137683A1 (en) * 2003-12-19 2005-06-23 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050154452A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US8309112B2 (en) 2003-12-24 2012-11-13 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
US7303758B2 (en) 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US20050159809A1 (en) * 2004-01-21 2005-07-21 Medtronic Vascular, Inc. Implantable medical devices for treating or preventing restenosis
US20050182474A1 (en) * 2004-02-13 2005-08-18 Medtronic Vascular, Inc. Coated stent having protruding crowns and elongated struts
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US8828416B2 (en) 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US8685431B2 (en) 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
WO2005089855A1 (en) * 2004-03-19 2005-09-29 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US8431145B2 (en) * 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7875282B2 (en) * 2004-03-22 2011-01-25 Cordis Corporation Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
US20050208093A1 (en) * 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20050214339A1 (en) 2004-03-29 2005-09-29 Yiwen Tang Biologically degradable compositions for medical applications
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US20060083772A1 (en) * 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
US20050228490A1 (en) * 2004-04-09 2005-10-13 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US8007737B2 (en) 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US20060063973A1 (en) 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US7462175B2 (en) 2004-04-21 2008-12-09 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US7559925B2 (en) 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20070208252A1 (en) 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US7419497B2 (en) 2004-04-21 2008-09-02 Acclarent, Inc. Methods for treating ethmoid disease
CN1569270B (en) * 2004-04-29 2011-06-29 上海瑞邦生物材料有限公司 Method for preparing cardiovascular drug eluting stent
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US20050265960A1 (en) * 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US20050267520A1 (en) * 2004-05-12 2005-12-01 Modesitt D B Access and closure device and method
US20050255230A1 (en) * 2004-05-17 2005-11-17 Clerc Claude O Method of manufacturing a covered stent
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
WO2006002112A1 (en) * 2004-06-18 2006-01-05 Surmodics, Inc. Devices, articles, coatings, and methods for controlled active agent release
US8568469B1 (en) 2004-06-28 2013-10-29 Advanced Cardiovascular Systems, Inc. Stent locking element and a method of securing a stent on a delivery system
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US8241554B1 (en) 2004-06-29 2012-08-14 Advanced Cardiovascular Systems, Inc. Method of forming a stent pattern on a tube
US7678133B2 (en) * 2004-07-10 2010-03-16 Arstasis, Inc. Biological tissue closure device and method
US8409167B2 (en) 2004-07-19 2013-04-02 Broncus Medical Inc Devices for delivering substances through an extra-anatomic opening created in an airway
US8747879B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device to reduce chance of late inflammatory response
US7971333B2 (en) 2006-05-30 2011-07-05 Advanced Cardiovascular Systems, Inc. Manufacturing process for polymetric stents
US8747878B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device by controlling crystalline structure
US8778256B1 (en) 2004-09-30 2014-07-15 Advanced Cardiovascular Systems, Inc. Deformation of a polymer tube in the fabrication of a medical article
US7731890B2 (en) 2006-06-15 2010-06-08 Advanced Cardiovascular Systems, Inc. Methods of fabricating stents with enhanced fracture toughness
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US9283099B2 (en) 2004-08-25 2016-03-15 Advanced Cardiovascular Systems, Inc. Stent-catheter assembly with a releasable connection for stent retention
WO2006024488A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
US7244443B2 (en) * 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US8517027B2 (en) 2004-09-03 2013-08-27 Boston Scientific Scimed, Inc. Reversible vessel seal
US7229471B2 (en) 2004-09-10 2007-06-12 Advanced Cardiovascular Systems, Inc. Compositions containing fast-leaching plasticizers for improved performance of medical devices
US20060062822A1 (en) * 2004-09-21 2006-03-23 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US8110211B2 (en) 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8858978B2 (en) 2004-09-28 2014-10-14 Atrium Medical Corporation Heat cured gel and method of making
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US7875233B2 (en) 2004-09-30 2011-01-25 Advanced Cardiovascular Systems, Inc. Method of fabricating a biaxially oriented implantable medical device
US8043553B1 (en) 2004-09-30 2011-10-25 Advanced Cardiovascular Systems, Inc. Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article
US8173062B1 (en) 2004-09-30 2012-05-08 Advanced Cardiovascular Systems, Inc. Controlled deformation of a polymer tube in fabricating a medical article
US7166680B2 (en) 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060083859A1 (en) * 2004-10-20 2006-04-20 Todd Robida Magnetic levitation system for coating a device, a method of using the system, and device made by the system
AU2005299672A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic RNAi agents for treating psoriasis
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US7958840B2 (en) * 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7481835B1 (en) 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US7588642B1 (en) 2004-11-29 2009-09-15 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method using a brush assembly
US8609123B2 (en) 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US20060115449A1 (en) * 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US20060124466A1 (en) * 2004-12-09 2006-06-15 Scimed Life Systems, Inc. Method and apparatus for coating a medical device by electroplating
US20060127443A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery
US20060129225A1 (en) * 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
KR100511618B1 (en) * 2005-01-17 2005-08-31 이경범 Multi-layer coating of drug release controllable coronary stent and method for manufacturing the same
WO2006081407A1 (en) * 2005-01-26 2006-08-03 Micrus Corporation Implantable microcoil with microscopic porosity surface
US20110054511A1 (en) * 2005-01-26 2011-03-03 Micrus Endovascular Corporation Adding microscopic porosity to the surface of a microcoil to be used for medical implantation
US8083793B2 (en) * 2005-02-28 2011-12-27 Medtronic, Inc. Two piece heart valves including multiple lobe valves and methods for implanting them
US20060195186A1 (en) 2005-02-28 2006-08-31 Drews Michael J Connectors for two piece heart valves and methods for implanting such heart valves
WO2006096251A2 (en) 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
JP5744376B2 (en) 2005-03-22 2015-07-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Treatment of protein degradation disorders
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
WO2006102359A2 (en) 2005-03-23 2006-09-28 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7513909B2 (en) * 2005-04-08 2009-04-07 Arbor Surgical Technologies, Inc. Two-piece prosthetic valves with snap-in connection and methods for use
US7381048B2 (en) 2005-04-12 2008-06-03 Advanced Cardiovascular Systems, Inc. Stents with profiles for gripping a balloon catheter and molds for fabricating stents
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8574259B2 (en) * 2005-05-10 2013-11-05 Lifescreen Sciences Llc Intravascular filter with drug reservoir
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
US8241325B2 (en) * 2005-05-12 2012-08-14 Arstasis, Inc. Access and closure device and method
US8211169B2 (en) 2005-05-27 2012-07-03 Medtronic, Inc. Gasket with collar for prosthetic heart valves and methods for using them
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US7823533B2 (en) 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
ES2691646T3 (en) 2005-07-15 2018-11-28 Micell Technologies, Inc. Polymer coatings containing controlled morphology drug powder
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20070027530A1 (en) * 2005-07-26 2007-02-01 Medtronic Vascular, Inc. Intraluminal device, catheter assembly, and method of use thereof
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US7658880B2 (en) 2005-07-29 2010-02-09 Advanced Cardiovascular Systems, Inc. Polymeric stent polishing method and apparatus
WO2007024649A2 (en) * 2005-08-19 2007-03-01 X-Cell Medical Incorporated Methods of treating and preventing acute myocardial infarction
US9248034B2 (en) 2005-08-23 2016-02-02 Advanced Cardiovascular Systems, Inc. Controlled disintegrating implantable medical devices
US20070048350A1 (en) 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US20070067020A1 (en) * 2005-09-22 2007-03-22 Medtronic Vasular, Inc. Intraluminal stent, delivery system, and a method of treating a vascular condition
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US20070104753A1 (en) * 2005-11-04 2007-05-10 Aiden Flanagan Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
US20070116736A1 (en) 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US20070128242A1 (en) * 2005-12-01 2007-06-07 Zhao Jonathan Z Polymeric compositions for controlled release or delivery of pharmacologically active agents
US20070128246A1 (en) * 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US7833261B2 (en) * 2005-12-12 2010-11-16 Advanced Cardiovascular Systems, Inc. Severable support for a stent
US7591841B2 (en) 2005-12-16 2009-09-22 Advanced Cardiovascular Systems, Inc. Implantable devices for accelerated healing
US7638156B1 (en) 2005-12-19 2009-12-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for selectively coating a medical article
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US7951185B1 (en) 2006-01-06 2011-05-31 Advanced Cardiovascular Systems, Inc. Delivery of a stent at an elevated temperature
US7967857B2 (en) 2006-01-27 2011-06-28 Medtronic, Inc. Gasket with spring collar for prosthetic heart valves and methods for making and using them
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
WO2007089881A2 (en) 2006-01-31 2007-08-09 Regents Of The University Of Minnesota Electrospray coating of objects
CA2641117C (en) 2006-01-31 2018-01-02 Nanocopoeia, Inc. Nanoparticle coating of surfaces
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007095584A2 (en) 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
US7601383B2 (en) 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
EP1832289A3 (en) * 2006-03-08 2007-12-12 Sahajanand Medical Technologies PVT. ltd Compositions and coatings for implantable medical devices
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US7881808B2 (en) * 2006-03-29 2011-02-01 Cardiac Pacemakers, Inc. Conductive polymeric coating with optional biobeneficial topcoat for a medical lead
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US7964210B2 (en) 2006-03-31 2011-06-21 Abbott Cardiovascular Systems Inc. Degradable polymeric implantable medical devices with a continuous phase and discrete phase
PL2019657T3 (en) 2006-04-26 2015-10-30 Micell Technologies Inc Coatings containing multiple drugs
WO2007130881A2 (en) 2006-04-29 2007-11-15 Arbor Surgical Technologies, Inc. Multiple component prosthetic heart valve assemblies and apparatus and methods for delivering them
US20070254003A1 (en) * 2006-05-01 2007-11-01 Pu Zhou Non-sticky coatings with therapeutic agents for medical devices
US20070259101A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Microporous coating on medical devices
CA2654540C (en) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US7761968B2 (en) 2006-05-25 2010-07-27 Advanced Cardiovascular Systems, Inc. Method of crimping a polymeric stent
US7951194B2 (en) 2006-05-26 2011-05-31 Abbott Cardiovascular Sysetms Inc. Bioabsorbable stent with radiopaque coating
US8752267B2 (en) 2006-05-26 2014-06-17 Abbott Cardiovascular Systems Inc. Method of making stents with radiopaque markers
US8343530B2 (en) 2006-05-30 2013-01-01 Abbott Cardiovascular Systems Inc. Polymer-and polymer blend-bioceramic composite implantable medical devices
US7959940B2 (en) 2006-05-30 2011-06-14 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical devices
US7842737B2 (en) 2006-09-29 2010-11-30 Abbott Cardiovascular Systems Inc. Polymer blend-bioceramic composite implantable medical devices
US20070282434A1 (en) * 2006-05-30 2007-12-06 Yunbing Wang Copolymer-bioceramic composite implantable medical devices
US8034287B2 (en) 2006-06-01 2011-10-11 Abbott Cardiovascular Systems Inc. Radiation sterilization of medical devices
US8486135B2 (en) 2006-06-01 2013-07-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from branched polymers
US20070286882A1 (en) * 2006-06-09 2007-12-13 Yiwen Tang Solvent systems for coating medical devices
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
US8333000B2 (en) 2006-06-19 2012-12-18 Advanced Cardiovascular Systems, Inc. Methods for improving stent retention on a balloon catheter
US9072820B2 (en) 2006-06-26 2015-07-07 Advanced Cardiovascular Systems, Inc. Polymer composite stent with polymer particles
US8128688B2 (en) 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2008002778A2 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
US7794776B1 (en) 2006-06-29 2010-09-14 Abbott Cardiovascular Systems Inc. Modification of polymer stents with radiation
US7740791B2 (en) 2006-06-30 2010-06-22 Advanced Cardiovascular Systems, Inc. Method of fabricating a stent with features by blow molding
US7823263B2 (en) 2006-07-11 2010-11-02 Abbott Cardiovascular Systems Inc. Method of removing stent islands from a stent
US7998404B2 (en) * 2006-07-13 2011-08-16 Advanced Cardiovascular Systems, Inc. Reduced temperature sterilization of stents
US7757543B2 (en) 2006-07-13 2010-07-20 Advanced Cardiovascular Systems, Inc. Radio frequency identification monitoring of stents
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US7794495B2 (en) 2006-07-17 2010-09-14 Advanced Cardiovascular Systems, Inc. Controlled degradation of stents
US7886419B2 (en) 2006-07-18 2011-02-15 Advanced Cardiovascular Systems, Inc. Stent crimping apparatus and method
US8506984B2 (en) * 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
US8016879B2 (en) 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
US9173733B1 (en) 2006-08-21 2015-11-03 Abbott Cardiovascular Systems Inc. Tracheobronchial implantable medical device and methods of use
US8007857B1 (en) 2006-09-08 2011-08-30 Abbott Cardiovascular Systems Inc. Methods for controlling the release rate and improving the mechanical properties of a stent coating
US7638159B2 (en) * 2006-09-12 2009-12-29 Boston Scientific Scimed, Inc. Liquid masking for selective coating of a stent
US7923022B2 (en) 2006-09-13 2011-04-12 Advanced Cardiovascular Systems, Inc. Degradable polymeric implantable medical devices with continuous phase and discrete phase
JP2010503469A (en) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド Medical device having drug-eluting film
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
WO2008042909A2 (en) * 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
WO2008051342A2 (en) * 2006-10-20 2008-05-02 Boston Scientific Limited Reduction of burst release from therapeutically treated medical devices
CN102886326A (en) 2006-10-23 2013-01-23 米歇尔技术公司 Holder for electrically charging a substrate during coating
WO2008051344A2 (en) * 2006-10-25 2008-05-02 Boston Scientific Limited Method and apparatus for coating a medical device by electroless plating
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US8099849B2 (en) 2006-12-13 2012-01-24 Abbott Cardiovascular Systems Inc. Optimizing fracture toughness of polymeric stent
JP2010512947A (en) * 2006-12-20 2010-04-30 ボストン サイエンティフィック リミテッド Stent with coating for delivering therapeutic agent
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
CN101711137B (en) 2007-01-08 2014-10-22 米歇尔技术公司 Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US7938286B2 (en) * 2007-02-13 2011-05-10 Gateway Plastics, Inc. Container system
US20080200421A1 (en) 2007-02-21 2008-08-21 Zhao Jonathon Z Coating for a medical device having an anti-thrombotic conjugate
US20090281059A1 (en) 2007-02-21 2009-11-12 Robert Falotico Coating for a medical device having an anti-thrombotic conjugate
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8646444B2 (en) * 2007-03-27 2014-02-11 Electrolux Home Products, Inc. Glide rack
US20080241215A1 (en) 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8262723B2 (en) 2007-04-09 2012-09-11 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from polymer blends with star-block copolymers
US8093039B2 (en) * 2007-04-10 2012-01-10 The Trustees Of The Stevens Institute Of Technology Surfaces differentially adhesive to eukaryotic cells and non-eukaryotic cells
EP2146758A4 (en) * 2007-04-17 2012-11-21 Micell Technologies Inc Stents having biodegradable layers
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8383156B2 (en) * 2007-04-30 2013-02-26 Cordis Corporation Coating for a medical device having an anti-thrombotic conjugate
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
EP2170418B1 (en) 2007-05-25 2016-03-16 Micell Technologies, Inc. Polymer films for medical device coating
US8802184B2 (en) * 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
US7829008B2 (en) 2007-05-30 2010-11-09 Abbott Cardiovascular Systems Inc. Fabricating a stent from a blow molded tube
US7959857B2 (en) 2007-06-01 2011-06-14 Abbott Cardiovascular Systems Inc. Radiation sterilization of medical devices
US8293260B2 (en) 2007-06-05 2012-10-23 Abbott Cardiovascular Systems Inc. Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices
US8202528B2 (en) 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
US20090018643A1 (en) * 2007-06-11 2009-01-15 Nanovasc, Inc. Stents
US8425591B1 (en) 2007-06-11 2013-04-23 Abbott Cardiovascular Systems Inc. Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US7901452B2 (en) 2007-06-27 2011-03-08 Abbott Cardiovascular Systems Inc. Method to fabricate a stent having selected morphology to reduce restenosis
US7955381B1 (en) 2007-06-29 2011-06-07 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20090011117A1 (en) * 2007-07-03 2009-01-08 Endotronix, Inc. Methods for texturing a surface of an endovascular implant
US20090018646A1 (en) 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
JP2010535541A (en) 2007-08-03 2010-11-25 ボストン サイエンティフィック リミテッド Coating for medical devices with large surface area
US20090041845A1 (en) * 2007-08-08 2009-02-12 Lothar Walter Kleiner Implantable medical devices having thin absorbable coatings
US8333795B2 (en) * 2007-08-27 2012-12-18 Boston Scientific Scimed, Inc. Bulging balloon for bifurcation catheter assembly and methods
US20090069878A1 (en) * 2007-08-27 2009-03-12 Boston Scientific Scimed, Inc. Bifurcation post-dilatation balloon and methods
US8409272B2 (en) 2007-09-04 2013-04-02 Japan Stent Technology Co., Ltd. Sustained drug-releasing stent
US20090074831A1 (en) 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
US9775882B2 (en) * 2007-09-20 2017-10-03 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090105744A1 (en) * 2007-10-17 2009-04-23 Modesitt D Bruce Methods for forming tracts in tissue
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118818A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8512731B2 (en) * 2007-11-13 2013-08-20 Medtronic Minimed, Inc. Antimicrobial coatings for medical devices and methods for making and using them
CA2705764C (en) 2007-11-14 2016-08-02 Biosensors International Group, Ltd. Automated stent coating apparatus and method
US8016880B2 (en) * 2007-11-16 2011-09-13 Medtronic Vascular, Inc. Stent having spiral channel for drug delivery
US8211489B2 (en) * 2007-12-19 2012-07-03 Abbott Cardiovascular Systems, Inc. Methods for applying an application material to an implantable device
US8361538B2 (en) 2007-12-19 2013-01-29 Abbott Laboratories Methods for applying an application material to an implantable device
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
AU2008343843A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
BRPI0908500A8 (en) 2008-02-22 2018-10-23 Micro Therapeutics Inc imaging methods of restoration of thrombus-occluded blood vessel blood flow, partial or substantial dissolution and thrombus dislocation, self-expanding thrombus removal equipment and integrated removable thrombus mass
US9603980B2 (en) 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
WO2009146209A1 (en) 2008-04-17 2009-12-03 Micell Technologies, Inc. Stents having bioabsorbable layers
EP2271380B1 (en) 2008-04-22 2013-03-20 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
WO2009155715A1 (en) * 2008-06-26 2009-12-30 Ao Technology Ag Bone fixation device with cover
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
US20100016890A1 (en) * 2008-07-17 2010-01-21 Steve Tsai Spool Dip And Overcoat Process For Medical Devices
EP2312993A4 (en) * 2008-07-21 2015-03-11 Arstasis Inc Devices, methods, and kits for forming tracts in tissue
CA2731493A1 (en) * 2008-07-21 2010-01-28 Arstasis, Inc. Devices and methods for forming tracts in tissue
KR101708946B1 (en) * 2008-07-23 2017-02-21 다나-파버 캔서 인스티튜트 인크. Deacetylase inhibitors and uses thereof
JP5676446B2 (en) 2008-07-30 2015-02-25 アクラレント インコーポレイテッド Sinus mouth finder
WO2010017451A2 (en) 2008-08-07 2010-02-11 Exogenesis Corporation Medical device for bone implant and method for producing such a device
US8216498B2 (en) 2008-09-10 2012-07-10 Boston Scientific Scimed, Inc. Catheter having a coextruded fluoropolymer layer
EP2323724A1 (en) 2008-09-18 2011-05-25 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8049061B2 (en) 2008-09-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US8226603B2 (en) 2008-09-25 2012-07-24 Abbott Cardiovascular Systems Inc. Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8076529B2 (en) 2008-09-26 2011-12-13 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2385960B1 (en) 2009-01-12 2020-03-11 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc Drug delivery medical device
US7978742B1 (en) 2010-03-24 2011-07-12 Corning Incorporated Methods for operating diode lasers
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
JP2012522589A (en) 2009-04-01 2012-09-27 ミシェル テクノロジーズ,インコーポレイテッド Covered stent
CA2757455C (en) * 2009-04-03 2017-08-22 Ashland Licensing And Intellectual Property Llc Ultraviolet radiation curable pressure sensitive acrylic adhesive
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
EP2419058B1 (en) 2009-04-17 2018-02-28 Micell Technologies, Inc. Stents having controlled elution
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
CA2761677A1 (en) * 2009-05-15 2010-11-18 Arstasis, Inc. Devices, methods and kits for forming tracts in tissue
CN102449429B (en) * 2009-05-26 2014-04-23 乌多·W·布赫 Wet paint coating thickness measurement method and instrument
US9181401B2 (en) 2009-06-15 2015-11-10 Dsm Ip Assets B.V. Phosphorylcholine-based amphiphilic silicones for medical applications
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
JP5933434B2 (en) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Method for producing drug delivery balloon
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
CN102573940B (en) 2009-08-21 2015-04-01 心脏起搏器公司 Crosslinkable polyisobutylene-based polymers and medical devices containing the same
US8753708B2 (en) * 2009-09-02 2014-06-17 Cardiac Pacemakers, Inc. Solventless method for forming a coating on a medical electrical lead body
US8374704B2 (en) 2009-09-02 2013-02-12 Cardiac Pacemakers, Inc. Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same
US8644952B2 (en) 2009-09-02 2014-02-04 Cardiac Pacemakers, Inc. Medical devices including polyisobutylene based polymers and derivatives thereof
JP2012235797A (en) * 2009-09-18 2012-12-06 Terumo Corp Stent
EP2480140A1 (en) * 2009-09-22 2012-08-01 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
WO2011059123A1 (en) * 2009-11-11 2011-05-19 주식회사 메디프렉스 Heparin compound bound to adhesive material, preparation method thereof, solid surface coating agent containing same as active ingredient, and coating method of solid surface using same
EP2501431B1 (en) 2009-11-19 2020-01-08 Wellinq Medical B.V. Narrow profile composition-releasing expandable medical balloon catheter
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
KR101808874B1 (en) 2010-01-22 2018-01-18 에이스틸론 파마수티컬스 인코포레이티드 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
WO2011119536A1 (en) 2010-03-22 2011-09-29 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US8389041B2 (en) 2010-06-17 2013-03-05 Abbott Cardiovascular Systems, Inc. Systems and methods for rotating and coating an implantable device
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US9662677B2 (en) 2010-09-15 2017-05-30 Abbott Laboratories Drug-coated balloon with location-specific plasma treatment
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
JP6041808B2 (en) 2010-11-16 2016-12-14 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. Pyrimidine hydroxyl amide compounds as protein deacetylase inhibitors and methods of use thereof
CA2823355C (en) 2010-12-30 2017-08-22 Micell Technologies, Inc. Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
US20140213971A1 (en) 2011-04-27 2014-07-31 Mark J. Dolan Nerve impingement systems including an intravascular prosthesis and an extravascular prosthesis and associated systems and methods
US8709034B2 (en) 2011-05-13 2014-04-29 Broncus Medical Inc. Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US9345532B2 (en) 2011-05-13 2016-05-24 Broncus Medical Inc. Methods and devices for ablation of tissue
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CA2852260C (en) 2011-10-18 2020-09-22 Micell Technologies, Inc. Drug delivery medical device
WO2013078235A1 (en) 2011-11-23 2013-05-30 Broncus Medical Inc Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
WO2013103514A1 (en) 2012-01-04 2013-07-11 The Trustees Of The Stevens Institute Of Technology Clay-containing thin films as carriers of absorbed molecules
US20130317438A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
US20130317481A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
JP6549482B2 (en) 2012-06-01 2019-07-24 サーモディクス,インコーポレイテッド Device and method for coating a balloon catheter
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
EP3345597A3 (en) 2012-09-19 2018-08-22 Faller & Williams Technology, LLC Pkc delta inhibitors for use as therapeutics
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
EP2922888B1 (en) 2012-11-21 2021-08-18 The University of Massachusetts High strength polyisobutylene polyurethanes
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
CA2905419C (en) 2013-03-12 2020-04-28 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9545301B2 (en) 2013-03-15 2017-01-17 Covidien Lp Coated medical devices and methods of making and using same
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
AU2014265460B2 (en) 2013-05-15 2018-10-18 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9668890B2 (en) 2013-11-22 2017-06-06 Covidien Lp Anti-thrombogenic medical devices and methods
JP2017505817A (en) 2014-02-04 2017-02-23 アボット カーディオバスキュラー システムズ インコーポレイテッド Drug delivery scaffold or stent having a coating based on NOVOLIMUS and lactide so that the binding of NOVOLIMUS to the coating is minimized
CN106535826A (en) 2014-06-24 2017-03-22 怡康医疗股份有限公司 Improved metal alloys for medical devices
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
SE538635C2 (en) * 2014-09-15 2016-10-04 Observe Medical Aps Method for sterilising a body fluid drainage system
US11090914B2 (en) * 2014-09-16 2021-08-17 Smilesonica Inc. Silicone and polymer substrate composite materials, methods, and uses of the same
US9789228B2 (en) 2014-12-11 2017-10-17 Covidien Lp Antimicrobial coatings for medical devices and processes for preparing such coatings
JP6815318B2 (en) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
WO2018148230A1 (en) 2017-02-09 2018-08-16 Med-El Elektromedizinische Geraete Gmbh Implantable electrode with dexamethasone coating
WO2018165273A1 (en) 2017-03-07 2018-09-13 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
WO2019036544A1 (en) 2017-08-17 2019-02-21 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
WO2019143629A1 (en) 2018-01-17 2019-07-25 Cardiac Pacemakers, Inc. End-capped polyisobutylene polyurethane
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
RU2737827C1 (en) * 2019-10-21 2020-12-03 Федеральное государственное бюджетное учреждение науки Институт металлургии и материаловедения им. А.А. Байкова Российской академии наук (ИМЕТ РАН) Method of producing biocompatible composite material with nanostructure titanium nickelide base and biodegradable drug-containing polylactide with heparin
WO2021152554A1 (en) 2020-01-31 2021-08-05 Fernando Biyagamage Ruchika Use of an anticoagulant inhibitor for the prevention of blood feeding by parasites or insects

Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168565A (en) * 1959-11-20 1965-02-02 Richardson Merrell Inc Trifluoromethyl derivatives of amino triarylethanols, -ethanes, and -ethylenes
US3634517A (en) * 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US3932627A (en) * 1974-02-04 1976-01-13 Rescue Products, Inc. Siver-heparin-allantoin complex
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4310523A (en) * 1978-04-17 1982-01-12 Schering Aktiengesellschaft Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
US4315028A (en) * 1978-12-22 1982-02-09 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US4317915A (en) * 1976-08-23 1982-03-02 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4428963A (en) * 1976-08-23 1984-01-31 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4900561A (en) * 1989-01-03 1990-02-13 Zinpro Corporation Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements
US4906452A (en) * 1985-10-17 1990-03-06 Neorx Corporation Trichothecene conjugates and methods of use
US4984594A (en) * 1989-10-27 1991-01-15 Shell Oil Company Vacuum method for removing soil contamination utilizing surface electrical heating
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US4990158A (en) * 1989-05-10 1991-02-05 United States Surgical Corporation Synthetic semiabsorbable tubular prosthesis
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US4994384A (en) * 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
US4994033A (en) * 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US4996225A (en) * 1982-06-25 1991-02-26 Farmos Group Ltd. Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5082834A (en) * 1978-05-30 1992-01-21 Sorensen John R J Anti-inflammatory and anti-ulcer compounds and process
US5176617A (en) * 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5180376A (en) * 1990-05-01 1993-01-19 Cathco, Inc. Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5182317A (en) * 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5185408A (en) * 1987-12-17 1993-02-09 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5188791A (en) * 1990-04-02 1993-02-23 Savoie Refractaires Concrete composition for the manufacture of moulds, mould and process for the manufacture of a mould
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280109A (en) * 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5282785A (en) * 1990-06-15 1994-02-01 Cortrak Medical, Inc. Drug delivery apparatus and method
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5282823A (en) * 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5288735A (en) * 1989-05-02 1994-02-22 Trager Seymour F Treatment of glaucoma
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5385935A (en) * 1992-09-14 1995-01-31 Kissei Pharmaceutical Co., Ltd. Method for the inhibition of restenosis associated with coronary intervention
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5393763A (en) * 1992-07-28 1995-02-28 Eli Lilly And Company Methods for inhibiting bone loss
US5480904A (en) * 1993-10-28 1996-01-02 Eli Lilly And Company Methods for inhibiting uterine fibrosis
US5480903A (en) * 1993-03-11 1996-01-02 Zymogenetics, Inc. 3,4-diarylchromans for inhibiting calmodulin activity
US5480888A (en) * 1992-01-17 1996-01-02 Daiichi Pharmaceutical Co., Ltd. Inhibitor for restenosis after percutaneous coronary arterioplasty
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5484798A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US5484797A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Naphthly compounds, intermediates, processes, compositions, and method for inhibiting endometrosis
US5486357A (en) * 1990-11-08 1996-01-23 Cordis Corporation Radiofrequency plasma biocompatibility treatment of inside surfaces
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5491159A (en) * 1994-08-30 1996-02-13 American Home Products Corporation 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents
US5492926A (en) * 1993-10-15 1996-02-20 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5492895A (en) * 1992-02-14 1996-02-20 Corvas International, Inc. Inhibitors of thrombosis
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5492922A (en) * 1995-02-28 1996-02-20 Eli Lilly And Company Benzothiophene compounds intermediate compositions and methods for inhibiting aortal smooth muscle proliferation
US5493931A (en) * 1994-02-14 1996-02-27 Grand Haven Stamped Products Company, Div. Of Jsj Corp. Vehicle shifter
US5591227A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Drug eluting stent
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5597578A (en) * 1989-09-11 1997-01-28 Oncogen TGF-β protein compositions for inhibition of cell proliferation
US5599844A (en) * 1993-05-13 1997-02-04 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5605700A (en) * 1992-04-03 1997-02-25 Orion-Yhtyma Oy Topical administration of toremifene and its metabolites
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5863285A (en) * 1997-01-30 1999-01-26 Cordis Corporation Balloon catheter with radioactive means
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US6013099A (en) * 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves
US6171609B1 (en) * 1995-02-15 2001-01-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20030039675A1 (en) * 1993-01-28 2003-02-27 Angiotech Pharmaceuticals, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US6689159B2 (en) * 1991-10-28 2004-02-10 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
SE8200751L (en) * 1982-02-09 1983-08-10 Olle Larm PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS
SE445884B (en) * 1982-04-30 1986-07-28 Medinvent Sa DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION
WO1986007541A1 (en) 1985-06-19 1986-12-31 Yasushi Zyo Composition which can impart antithrombotic ability and medical apparatus to be in contact with blood
SE453258B (en) * 1986-04-21 1988-01-25 Medinvent Sa ELASTIC, SELF-EXPANDING PROTEST AND PROCEDURE FOR ITS MANUFACTURING
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4916193A (en) * 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5019096A (en) * 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5262451A (en) * 1988-06-08 1993-11-16 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5338770A (en) * 1988-06-08 1994-08-16 Cardiopulmonics, Inc. Gas permeable thrombo-resistant coatings and methods of manufacture
US5092877A (en) * 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5226913A (en) * 1988-09-01 1993-07-13 Corvita Corporation Method of making a radially expandable prosthesis
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5165952A (en) * 1989-01-18 1992-11-24 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
KR920000459B1 (en) * 1989-12-13 1992-01-14 재단법인 한국화학연구소 Artificial vascular tube
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JPH05502179A (en) * 1990-02-28 1993-04-22 メドトロニック インコーポレーテッド Tubular organ drug elution device
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
JPH0744950B2 (en) 1990-04-17 1995-05-17 住友ベークライト株式会社 Antithrombogenic material and method for producing the same
AU7998091A (en) * 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5258020A (en) * 1990-09-14 1993-11-02 Michael Froix Method of using expandable polymeric stent with memory
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
AU1579092A (en) * 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH06121828A (en) 1992-10-13 1994-05-06 Sumitomo Bakelite Co Ltd Medical balloon catheter
EP0597593A1 (en) * 1992-10-30 1994-05-18 Medtronic, Inc. Thromboresistant articles
US5449382A (en) * 1992-11-04 1995-09-12 Dayton; Michael P. Minimally invasive bioactivated endoprosthesis for vessel repair
US5578075B1 (en) * 1992-11-04 2000-02-08 Daynke Res Inc Minimally invasive bioactivated endoprosthesis for vessel repair
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5443458A (en) * 1992-12-22 1995-08-22 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method of manufacture
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
EP0689465A1 (en) * 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
BE1006819A7 (en) * 1993-03-24 1994-12-13 Dsb Nv Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES.
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
DE69412474T2 (en) * 1993-04-28 1998-12-17 Focal Inc DEVICE, PRODUCT AND USE REGARDING INTRALUMINAL PHOTOTHERMO MOLDING
IT1276342B1 (en) * 1993-06-04 1997-10-30 Ist Naz Stud Cura Dei Tumori METAL STENT COVERED WITH BIOCOMPATIBLE POLYMERIC MATERIAL
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5643580A (en) * 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
US5700559A (en) * 1994-12-16 1997-12-23 Advanced Surface Technology Durable hydrophilic surface coatings
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
CA2216943C (en) * 1995-04-19 2003-06-17 Schneider (Usa) Inc. Drug release coated stent
US5688855A (en) * 1995-05-01 1997-11-18 S.K.Y. Polymers, Inc. Thin film hydrophilic coatings
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168565A (en) * 1959-11-20 1965-02-02 Richardson Merrell Inc Trifluoromethyl derivatives of amino triarylethanols, -ethanes, and -ethylenes
US3634517A (en) * 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US3932627A (en) * 1974-02-04 1976-01-13 Rescue Products, Inc. Siver-heparin-allantoin complex
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4317915A (en) * 1976-08-23 1982-03-02 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4428963A (en) * 1976-08-23 1984-01-31 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4310523A (en) * 1978-04-17 1982-01-12 Schering Aktiengesellschaft Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
US5082834A (en) * 1978-05-30 1992-01-21 Sorensen John R J Anti-inflammatory and anti-ulcer compounds and process
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4315028A (en) * 1978-12-22 1982-02-09 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US4996225A (en) * 1982-06-25 1991-02-26 Farmos Group Ltd. Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5482851A (en) * 1985-03-22 1996-01-09 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4906452A (en) * 1985-10-17 1990-03-06 Neorx Corporation Trichothecene conjugates and methods of use
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4994384A (en) * 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US5185408A (en) * 1987-12-17 1993-02-09 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5182317A (en) * 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US4900561A (en) * 1989-01-03 1990-02-13 Zinpro Corporation Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements
US5288735A (en) * 1989-05-02 1994-02-22 Trager Seymour F Treatment of glaucoma
US4990158A (en) * 1989-05-10 1991-02-05 United States Surgical Corporation Synthetic semiabsorbable tubular prosthesis
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US4994033A (en) * 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US5597578A (en) * 1989-09-11 1997-01-28 Oncogen TGF-β protein compositions for inhibition of cell proliferation
US4984594A (en) * 1989-10-27 1991-01-15 Shell Oil Company Vacuum method for removing soil contamination utilizing surface electrical heating
US5176617A (en) * 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5188791A (en) * 1990-04-02 1993-02-23 Savoie Refractaires Concrete composition for the manufacture of moulds, mould and process for the manufacture of a mould
US5180376A (en) * 1990-05-01 1993-01-19 Cathco, Inc. Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters
US5282785A (en) * 1990-06-15 1994-02-01 Cortrak Medical, Inc. Drug delivery apparatus and method
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5486357A (en) * 1990-11-08 1996-01-23 Cordis Corporation Radiofrequency plasma biocompatibility treatment of inside surfaces
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
US6689159B2 (en) * 1991-10-28 2004-02-10 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5480888A (en) * 1992-01-17 1996-01-02 Daiichi Pharmaceutical Co., Ltd. Inhibitor for restenosis after percutaneous coronary arterioplasty
US5280109A (en) * 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
US5492895A (en) * 1992-02-14 1996-02-20 Corvas International, Inc. Inhibitors of thrombosis
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
US5591227A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Drug eluting stent
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5282823A (en) * 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5605700A (en) * 1992-04-03 1997-02-25 Orion-Yhtyma Oy Topical administration of toremifene and its metabolites
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5393763A (en) * 1992-07-28 1995-02-28 Eli Lilly And Company Methods for inhibiting bone loss
US5385935A (en) * 1992-09-14 1995-01-31 Kissei Pharmaceutical Co., Ltd. Method for the inhibition of restenosis associated with coronary intervention
US20030039675A1 (en) * 1993-01-28 2003-02-27 Angiotech Pharmaceuticals, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5480903A (en) * 1993-03-11 1996-01-02 Zymogenetics, Inc. 3,4-diarylchromans for inhibiting calmodulin activity
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5599844A (en) * 1993-05-13 1997-02-04 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5492926A (en) * 1993-10-15 1996-02-20 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5480904A (en) * 1993-10-28 1996-01-02 Eli Lilly And Company Methods for inhibiting uterine fibrosis
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5493931A (en) * 1994-02-14 1996-02-27 Grand Haven Stamped Products Company, Div. Of Jsj Corp. Vehicle shifter
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5491159A (en) * 1994-08-30 1996-02-13 American Home Products Corporation 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents
US5484796A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting aortal smooth muscle cell proliferation
US5484798A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US5492921A (en) * 1994-09-20 1996-02-20 Eli Lilly And Company Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation
US5484797A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Naphthly compounds, intermediates, processes, compositions, and method for inhibiting endometrosis
US5484795A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting restenosis
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US6171609B1 (en) * 1995-02-15 2001-01-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5492922A (en) * 1995-02-28 1996-02-20 Eli Lilly And Company Benzothiophene compounds intermediate compositions and methods for inhibiting aortal smooth muscle proliferation
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5863285A (en) * 1997-01-30 1999-01-26 Cordis Corporation Balloon catheter with radioactive means
US6013099A (en) * 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6187370B1 (en) * 1998-04-29 2001-02-13 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7691401B2 (en) 2000-09-28 2010-04-06 Advanced Cardiovascular Systems, Inc. Poly(butylmethacrylate) and rapamycin coated stent
US8303609B2 (en) 2000-09-29 2012-11-06 Cordis Corporation Coated medical devices
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US20040098117A1 (en) * 2001-06-29 2004-05-20 Hossainy Syed F.A. Composite stent with regioselective material and a method of forming the same
US20070116856A1 (en) * 2001-06-29 2007-05-24 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
US8961584B2 (en) 2001-06-29 2015-02-24 Abbott Cardiovascular Systems Inc. Composite stent with regioselective material
US20070118212A1 (en) * 2001-06-29 2007-05-24 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
US8025916B2 (en) 2001-06-29 2011-09-27 Abbott Cardiovascular Systems Inc. Methods for forming a composite stent with regioselective material
US7658758B2 (en) 2001-09-07 2010-02-09 Innovational Holdings, Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20070082120A1 (en) * 2001-09-07 2007-04-12 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US8173199B2 (en) 2002-03-27 2012-05-08 Advanced Cardiovascular Systems, Inc. 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US9254202B2 (en) 2002-09-20 2016-02-09 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20060096660A1 (en) * 2002-09-20 2006-05-11 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US20060122697A1 (en) * 2002-09-20 2006-06-08 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
US8349390B2 (en) 2002-09-20 2013-01-08 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US20040238978A1 (en) * 2002-09-20 2004-12-02 Diaz Stephen Hunter Method and apparatus for loading a benefical agent into an expandable medical device
US8586069B2 (en) 2002-12-16 2013-11-19 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US20050287287A1 (en) * 2004-06-24 2005-12-29 Parker Theodore L Methods and systems for loading an implantable medical device with beneficial agent
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US9566373B2 (en) 2004-06-30 2017-02-14 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US9138337B2 (en) 2004-06-30 2015-09-22 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8067025B2 (en) 2006-02-17 2011-11-29 Advanced Cardiovascular Systems, Inc. Nitric oxide generating medical devices
US7713637B2 (en) 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US8596215B2 (en) 2006-05-04 2013-12-03 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8637110B2 (en) 2006-05-04 2014-01-28 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8741379B2 (en) 2006-05-04 2014-06-03 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8465789B2 (en) 2006-05-04 2013-06-18 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8304012B2 (en) 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US7775178B2 (en) 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US8568764B2 (en) 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US8029816B2 (en) 2006-06-09 2011-10-04 Abbott Cardiovascular Systems Inc. Medical device coated with a coating containing elastin pentapeptide VGVPG
US8062350B2 (en) 2006-06-14 2011-11-22 Abbott Cardiovascular Systems Inc. RGD peptide attached to bioabsorbable stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8808342B2 (en) 2006-06-14 2014-08-19 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8118863B2 (en) 2006-06-14 2012-02-21 Abbott Cardiovascular Systems Inc. RGD peptide attached to bioabsorbable stents
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8293367B2 (en) 2006-06-23 2012-10-23 Advanced Cardiovascular Systems, Inc. Nanoshells on polymers
US8592036B2 (en) 2006-06-23 2013-11-26 Abbott Cardiovascular Systems Inc. Nanoshells on polymers
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US20080033522A1 (en) * 2006-08-03 2008-02-07 Med Institute, Inc. Implantable Medical Device with Particulate Coating
US9682162B2 (en) 2006-08-15 2017-06-20 Abbott Cardiovascular Systems Inc. Sterilization methods for medical devices
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US20080097590A1 (en) * 2006-10-18 2008-04-24 Conor Medsystems, Inc. Systems and Methods for Producing a Medical Device
US20080095917A1 (en) * 2006-10-18 2008-04-24 Conor Medsystems, Inc. Systems and Methods for Producing a Medical Device
US20080097588A1 (en) * 2006-10-18 2008-04-24 Conor Medsystems, Inc. Systems and Methods for Producing a Medical Device
US8011316B2 (en) 2006-10-18 2011-09-06 Innovational Holdings, Llc Systems and methods for producing a medical device
US7997226B2 (en) 2006-10-18 2011-08-16 Innovational Holdings Llc Systems and methods for producing a medical device
US7854957B2 (en) 2006-10-18 2010-12-21 Innovational Holdings, Llc Systems and methods for producing a medical device
US8597673B2 (en) 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
US20080195079A1 (en) * 2007-02-07 2008-08-14 Cook Incorporated Medical device coatings for releasing a therapeutic agent at multiple rates
US8932345B2 (en) 2007-02-07 2015-01-13 Cook Medical Technologies Llc Medical device coatings for releasing a therapeutic agent at multiple rates
US9656003B2 (en) 2007-02-07 2017-05-23 Cook Medical Technologies Llc Medical device coatings for releasing a therapeutic agent at multiple rates
US8147769B1 (en) * 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US8524166B2 (en) 2007-05-16 2013-09-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation including a Chitooligosaccharide
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices

Also Published As

Publication number Publication date
ATE376431T1 (en) 2007-11-15
EP1019107B1 (en) 2006-07-12
US6358556B1 (en) 2002-03-19
DE69636351T3 (en) 2012-11-08
EP1559439A1 (en) 2005-08-03
EP1500407B1 (en) 2010-07-21
EP1500406A3 (en) 2007-10-24
EP1500407A3 (en) 2007-10-31
AU703805B2 (en) 1999-04-01
EP2082753A3 (en) 2009-12-30
EP1500406A2 (en) 2005-01-26
EP1019107B2 (en) 2012-07-25
NO981066D0 (en) 1998-03-11
DE69637302T2 (en) 2008-07-31
EP1559439B1 (en) 2007-10-24
JPH11500047A (en) 1999-01-06
MX9801941A (en) 1998-08-30
EP1647287A2 (en) 2006-04-19
IL123622A (en) 2004-01-04
US20020071902A1 (en) 2002-06-13
EP1500407A2 (en) 2005-01-26
ZA967625B (en) 1997-04-16
EP1019107A1 (en) 2000-07-19
KR19990044571A (en) 1999-06-25
CA2231727C (en) 2004-09-14
AU6965296A (en) 1997-04-01
DE69636351T2 (en) 2006-11-16
US5837313A (en) 1998-11-17
WO1997010011A1 (en) 1997-03-20
CA2231727A1 (en) 1997-03-20
IL123622A0 (en) 1998-10-30
BR9610607A (en) 1999-05-04
ES2295995T3 (en) 2008-04-16
EP1647287A3 (en) 2006-04-26
EP2082753A2 (en) 2009-07-29
NO981066L (en) 1998-05-08
ATE332715T1 (en) 2006-08-15
DE69637302D1 (en) 2007-12-06
DE69636351D1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
US5837313A (en) Drug release stent coating process
US6120536A (en) Medical devices with long term non-thrombogenic coatings
US6620194B2 (en) Drug coating with topcoat
US20060089705A1 (en) Drug release coated stent
CA2470709C (en) Stent with drug release coating
CA2598946A1 (en) Drug release stent coating process
MXPA98001941A (en) Procedure to cover a farm releasing fastening protesis
MXPA97004436A (en) Coating and procedure to cover a farm release fixer

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA

Free format text: MERGER;ASSIGNOR:BOSTON SCIENTIFIC SCIMED, INC.;REEL/FRAME:018454/0834

Effective date: 20050101

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:SCHNEIDER (USA) INC.;REEL/FRAME:018454/0858

Effective date: 19990427

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018454/0866

Effective date: 20050101

AS Assignment

Owner name: SCHNEIDER (USA) INC.,MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, NI;HELMUS, MICHAEL N.;SIGNING DATES FROM 19960109 TO 19960118;REEL/FRAME:024552/0778

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE